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Abstract 
Targeting the DNA Damage Response for the Treatment of Oral Mucosal HSV-1 
Infection 
William Edward Donegan III 
Jane Azizkhan-Clifford, Ph.D. 
 
Herpes simplex virus type 1 (HSV-1) is a highly prevalent pathogen that infects 67% of 
the world’s population. HSV-1 most commonly infects the oral mucosal epithelium and 
manifests as herpes simplex labialis (cold sore) or herpetic gingivostomatitis. Patients who have 
a compromised immune system are at serious risk for developing debilitating HSV-1 disease that 
can disseminate to internal organs and become life threatening. In these cases, reliance on 
therapeutics can cause the emergence of drug-resistant HSV-1 strains. The treatment options 
for drug-resistant HSV-1 infection are nonspecific and fraught with toxicity concerns. Thus, there 
is a critical need for the development of novel therapeutics.  
HSV-1 engages the cellular DNA damage response (DDR) by activating Ataxia 
Telangiectasia Mutated (ATM) and its major downstream target, Checkpoint Kinase 2 (Chk2). 
The activation of both these factors is required for productive infection, which makes them 
prime drug candidates. We demonstrate that small molecule inhibitors against ATM or Chk2 
suppresses wild type and acyclovir-resistant HSV-1 replication in normal human oral 
keratinocyte cells. Furthermore, topical application of ATM or Chk2 inhibitors reduces the 
severity of herpes simplex labialis in a mouse lip model. We also demonstrate for the first time 
xvi 
 
that ATM signaling is required for circularization of the HSV-1 genome. Interestingly, Chk2 is not 
required for HSV-1 genome circularization, which suggests that additional functions of the DDR 
are required for HSV-1 replication. We also elucidate that ATM can be activated at low levels 
independently of de novo synthesis, and robustly through the expression of ICP4. These data 
establish that targeting the DDR has the potential for treating oral mucosal HSV-1 disease, and 
further our understanding on how the DDR is utilized during HSV-1 infection. 
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Chapter 1: Clinical Manifestation of Oral Mucosal HSV-1 Infection 
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Introduction 
Herpes simplex virus (HSV) infections were first identified and recorded by the 
ancient Greeks. Hippocrates is credited for attributing the term “herpes” to describe 
lesions that appeared to creep or crawl across the skin (1). Herpes infections have 
persisted in nature over the two-plus millennia since Hippocrates’s initial 
characterization. A myriad of seminal discoveries in the past two centuries have greatly 
increased our understanding on the causative agents behind herpes infection. Vidal and 
Gruter were two of the early pioneers who demonstrated in the late 19th century and 
early 20th century that HSV was infectious and could be passed from one individual to 
another; Gruter is credited for being the first person to isolate HSV (2, 3). In 1938, Doerr 
proposed that HSV was the result of a virus-like causative agent (4). Also in the 1930’s, 
Andrews and Carmichael made a very important observation that recurrent HSV 
infections only occur in adults harboring neutralizing antibodies (5). This finding was 
paramount in developing the theory that HSV remains latent in an infected host. Burnet 
and Williams further expanded on this viewpoint when they proclaimed that HSV 
infections last for life and can be reactivated form latency by different physiological 
trauma (6). This was proven in 1971 when Jack Stevens and Margery Cook discovered 
that HSV-1 establishes latency in ganglia of neurons (7). In the 50 years following this 
important discovery, there has been a monumental increase in our understanding of 
HSV-1 on a molecular and physiological level due to technical advances of molecular 
tools and assays.   
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Herpesviridae  
All viruses classified in the Herpesviridae family share similar structural 
characteristics, including: a core containing double stranded DNA; a capsid that 
packages the DNA; a group of viral and cellular proteins that surround the capsid called 
tegument; and an envelope that contains glycoproteins (8, 9). Herpesvirions range from 
120 to 300 nm in diameter (8). In addition to sharing similar structural features, there 
are biological properties that are common across all herpesviruses: (i) Viral DNA gets 
replicated and packaged into capsids within the nucleus of the infected cell. (ii) 
Herpesviruses produce a large amount of progeny virions, which causes the infected cell 
to die. (iii) Herpesviruses establish latency within the host they infect. While viruses in 
the herpesviridae family share these common properties, they also differ greatly in 
regards to their range of hosts, the rate at which they multiply, the cell types they target 
for establishing latency, and the clinical manifestations that they produce.  
In 1978, the herpesvirus study group of the International Committee on 
Taxonomy of Viruses created 3 subfamilies under the family Herpesviridae to further 
classify the diversity of herpesviruses: Alphaherpesvirinae, Betaherpesvirinae, and 
Gammaherpesvirinae (10). Alphaherpesvirinae have short reproductive cycles which 
enables them to replicate and spread quickly in culture. They also have the ability to 
infect multiple hosts and predominantly establish latency in sensory ganglia. Viruses 
classified as Alphaherpesviruses include herpes simplex virus type 1 (HSV-1), herpes 
simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV). Alternatively, 
Betaherpesvirinae have a much slower replication rate that causes the infected cell to 
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become enlarged. The host range of this subfamily tends to be more restricted when 
compared to Alphaherpesvirinae, but this is not a strict requirement. Viruses in this 
subfamily establish latency in secretory glands, lymphoreticular cells, kidneys, and other 
tissues. Human cytomegalovirus (HCMV) is the most characterized virus in this 
subfamily. Gammaherpesvirinae viruses are the third subfamily of Herpesviridae and are 
furthered dichotomized into two genera: lymphocryptovirus and rhadinovirus. 
Gammaherpesviruses infect either T or B lymphocytes, and establish latency in 
lymphoid tissue (8). A unique feature of these viruses is their propensity to establish 
latency upon infection rather than trigger a lytic replicative stage, and as a result, many 
viruses in this subfamily do not replicate in cultured cells (8, 11). Gammaherpesviruses 
have long been thought to have a restricted host range, but more recent studies 
demonstrated that some viruses can infect a wider range of cells (12, 13). Two 
prominent human Gammaherpesviruses are Epstein Barr Virus (EBV) and Kaposi’s 
sarcoma-associated herpes virus (KHSV; HHV8). Interestingly, both of these viruses 
induce transformation of the host cell and have been associated with cancers (14). 
 
Herpes Simplex Virus Type 1 Epidemiology 
Herpes simplex virus type 1 (HSV-1) is an extremely prevalent virus that infects 
humans throughout the world. Sixty seven percent of the world’s population (3,709 
million people) between the ages of 0 and 49 are estimated to have HSV-1 infection 
(15). Primary HSV-1 infection typically occurs in childhood, and prevalence increases 
with age (16, 17). Measurement of HSV-1 infection is conducted through serologic tests 
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where blood samples are assayed for the presence of HSV-1 specific antibodies. 
Seroprevalence varies greatly across the 6 World Health Organization areas: Africa 
(87.00%), Eastern Mediterranean (75%), Western Pacific (73.48%), Europe (64.96%), 
South-Eastern Asia (58.48%), and Americas (43.99%) (15). There is additional variance 
within these geographical areas. For instance, HSV-1 seroprevalence rates in Europe 
differ greatly by country: Netherlands (42.7%), Finland (57%), Belgium (67%), Czech 
Republic (81%), Bulgaria (84%) (18, 19).  
In the United States, seroprevalence is estimated through data collected in the 
National Health and Nutrition Examination Survey (NHANES). The NHANES is conducted 
by the National Center for Health Statistics (NCHS) and consists of surveys combined 
with a physical examination that includes collection of urine and blood specimens (20). 
The NHANES surveys started in 1971 and occurred in a periodic fashion until 1999 when 
they were modified to a continuous basis. HSV serologic testing began with the third 
NHANES that took place from 1988 to 1994. This survey reported that 62.0% of the 
United States population was seropositive for HSV-1, with 45.7% of the age 14-19 
population being seropositive (21). Data collected from NHANES surveys between 1999 
and 2004 determined that 57.7% of the population were seropositive with 39.0% of the 
age 14-19 population testing positive (21). Most recently, data from the 2005 to 2010 
NHANES surveys was analyzed and determined that 53.9% of the population is 
seropositive, with 30% of the age 14-19 population testing positive (20).  
Analysis of the NHANES reports reveal a downward trend of HSV-1 
seroprevalence in the US over the past 30 years, which is most noticeable in the 14-19 
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year old population (20, 22). This downward trend of HSV-1 seroprevalence has also 
been noticed in other countries, such as England and Wales where HSV-1 
seroprevalence dropped in 10-14 year olds from 34% in 1986-7 to 24% in 1994-95 (22, 
23), and in the Netherlands where overall levels of seroprevalence dropped from 47.7% 
in 1995-6 to 42.7% in 2006-7 with a significant decrease in seroprevalence of children 
aged 6 months to 11 years old (18). It is predominantly thought that the lower incidence 
of HSV-1 infection, particularly in children, is due to better hygiene and overall improved 
living conditions (16, 20). While the declining rate of HSV-1 seroprevalence is certainly a 
positive observation for the health of the global population, it poses a new challenge 
where children do not develop protective antibodies. This has created a situation where 
individuals are coming into contact with HSV-1 for the first time during adolescence and 
adulthood, which is attributed to the increased incidence of genital HSV-1 infections (22, 
24-26). Despite the reduction in HSV-1 seroprevalence, an estimated 118 million new 
cases of HSV-1 infection occurred in the year 2012 alone and HSV-1 diseases remain a 
prominent health condition across the world (15). 
 
Oral Mucosal HSV-1 infection 
Introduction 
HSV-1 spreads when lesions containing actively replicating virus come into direct 
contact with a seronegative individual. HSV-1 can infect numerous parts of the body 
with the more common maladies arising as primary herpetic gingivostomatitis (intra oral 
mucosal tissue), herpes simplex labialis (lips), herpetic keratitis (eye), genitals and less 
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commonly as herpetic whitlow (fingers), herpes gladiatorum (skin), and herpetic sycosis 
(hair follicles) (23, 27). In patients with a compromised immune system, HSV-1 can 
disseminate to internal organs and cause esophagitis, hepatitis, pneumonitis, and, in 
very rare cases, encephalitis. 
The most frequent manifestations of HSV-1 disease occur intraorally as primary 
herpetic gingivostomatitis (PHGS) or in the lips as herpes simplex labialis (HSL). The virus 
is transmitted when a lesion or bodily fluid, commonly in the form of saliva, of an 
infected person comes in contact with the mucosal surface or abraded skin of an 
uninfected person (28). HSV-1 undergoes a lytic life cycle within the mucosal epithelial 
cells at the site of infection, which produces an ulcer or sore. The intraoral mucosa and 
the epithelium of the lips are both innervated with sensory neurons that converge at 
the trigeminal ganglion. HSV-1 particles that are produced from both PHGS and HSL 
infect the sensory neurons and travel in a retrograde manner to the trigeminal ganglion 
body where the virus establishes lifelong latency (27). In response to physical and 
emotional stressors, HSV-1 can be reactivated, travel along the sensory neurons back to 
the oral mucosa, and initiate another round of lytic infection (29). Recurrence of oral 
mucosal HSV-1 infection occurs predominantly as HSL, regardless of whether initial 
infection occurred by PHGS or HSL (28). There is no cure for HSV-1 infection, but 
therapeutic treatment for HSL is often desired to reduce the duration of painful 
outbreaks.   
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Primary Herpetic Gingivostomatitis 
Primary HSV-1 infection usually occurs as herpetic gingivostomatitis in children 
starting at the age of 6 months, which is when they lose the protective antibodies 
acquired from the mother (30). There are two predominant age groups where incidence 
of PHGS peaks: between 6 months and 5 years of age or in the early 20’s (23, 31). 
According to multiple studies, symptoms of PHGS are detected in either 10-12 % or 25-
30 % of infected children, which means that the majority of infections are asymptomatic 
(23, 32-35). Symptoms of PHGS can arise in the tongue, lips, gingivae, buccal mucosa, 
hard palate, or soft palate (23, 36). Initially, there is a 2-20 day incubation period 
followed by a 1-3 day prodromal phrase where fever, loss of appetite, malaise, myalgia, 
and nausea can all occur (30, 36-38) . The acute phase begins next and is characterized 
by the formation of numerous red vesicles that are 1-2 mm in size and very painful (23, 
31, 36, 39, 40). The small lesions proceed to break down and coalesce into bigger ulcers 
that are covered in a yellow-grey membrane surrounded by an erythematous halo (23, 
31, 36, 40). On average, lesions last for 12 days; it takes 6 days for the lesion to fully 
form and another 6 days for them to resolve (33). Viral shedding from sores can be 
detected, on average, during the first 7.3 days (33). Marginal gingivitis may occur with 
PHGS and appears 1 to 2 days after the prodromal phase (41). Most children with PHGS 
experience a fever for the first 4-5 days, and have difficulty eating and drinking due to 
the pain associated with symptoms (33). Dehydration is a serious concern that needs to 
be monitored throughout the duration of symptoms (33, 42). PHGS is a self-limiting 
disease and ulcers will heal on their own in 10-14 days without leaving a scar. Following 
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clearance of infection, patients remain infected with latent HSV-1. Interestingly, 
recurrence of infection in the intraoral mucosa is very rare and it is uncommon for HGS 
to occur again in patients (39). 
 
Recurrent Herpes Simplex Labialis  
Latent virus that results from primary infection can be reactivated by various 
triggers, such as sunlight/ultraviolet light, physical stress due to dental work or surgery, 
emotional stress, menses or hormone changes, fever, dehydration, upper respiratory 
infection, or immunosuppression (23, 43, 44). When HSV-1 is reactivated from the 
trigeminal ganglion it travels along sensory neurons to the outer surfaces of lips where a 
round of lytic infection manifests as HSL. For unknown reasons, recurrence 
predominantly takes form as HSL and very rarely as herpetic gingivostomatitis (28, 45). 
Since recurrence can occur throughout the patient’s lifetime, HSL is the most common 
manifestation of HSV-1 disease encountered and accounts for 90% of orofacial HSV-1 
infection (27). 
Recurrent HSL initiates with a prodromal phase in 46 to 60% of patients (40, 43, 
46). The prodromal phase represents the very initial stages of HSV-1 replication at the 
nerve endings and innervation into the mucosal epithelium (28). Prodromal symptoms 
consist of pain, tingling, a burning sensation, tenderness, itching, and erythema at the 
site of reactivation that last for up to 6 hours (40, 43, 46). In about 25% of prodromal 
occurrences, HSV-1 infection is aborted and HSL symptoms do not arise (46). However, 
progression towards HSL typically occurs with the appearance of small, fluid-filled 
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vesicles representing the first visual symptoms. The next 48 hours are the most painful 
portion of HSL for the patient and represent the biggest risk for spreading HSV-1 
because the virus is actively replicating (28, 47, 48). After 2 days, the vesicles rupture 
and form pustules or ulcers that rapidly crusts over. Healing is complete by 8-10 days 
generally without any sign of a scar. The size of lesions can vary, but patients who 
experience a prodromal phase tend to have larger lesions (49). Patients who experience 
symptomatic HSL typically have 1 or 2 outbreaks annually (50). In immunocompetent 
individuals, HSL is a self-limiting disease that does not require therapeutic treatment. 
However, 10-15% of patients that experience symptomatic HSL have 6 or more 
recurrences annually (50). For these patients and those with a compromised immune 
system, antiviral medication is prescribed. Therapeutic intervention is of paramount 
concern for immunocompromised patients (discussed below) because without 
treatment the virus can systemically disseminate and cause life-threatening disease. 
 
Therapeutic Management of Oral Mucosal HSV-1 Disease  
Introduction 
High rates of genomic replication are commonly seen in viral infections and 
contribute to a large production of progeny virus. This aspect of viral infection was 
targeted during the advent of antiviral chemotherapeutic synthesis in the 1950’s and 
1960’s through the development of nucleoside analogues (51). The rationale behind 
nucleoside analogues is that they get converted to nucleotide analogs within the cell 
and terminate viral replication when they get incorporated into synthesizing viral DNA 
11 
 
(51). The first antiviral nucleoside analog, idoxuridine (5-iodo-2′-deoxyuridine), was 
created by William H. Prusoff in 1959 (52). Idoxuridine is a 5-substituted 2′-deoxyuridine 
analog that substitutes for thymidine and inhibits HSV-1 DNA synthesis (53). Trifluridine 
(5-trifluoromethyl-2’-deoxythymidine) was later developed in 1964, and is another 5-
substituted 2’-deoxyuridine analog that inhibits viral DNA replication in manner similar 
to idoxuridine (54). Unfortunately, these analogues get converted into nucleotides by 
cellular kinases and get incorporated by both viral and cellular DNA polymerases into 
synthesizing DNA. As a result, these compounds are not specific to HSV-1 infected cells 
and cause cytotoxic side-effects by inhibiting normal cellular DNA replication in 
uninfected cells (55-57). Despite this drawback, trifluridine is still used for the treatment 
of ocular HSV-1 infections (58). While the rationale of using nucleotide analogs was 
sound, the majority of early compounds produced during this time had significant 
toxicity and solubility drawbacks that prevented them from being further developed as 
antiviral therapeutics.  
 
Acyclovir 
A major triumph in the treatment of HSV diseases was the discovery of an acyclic 
guanosine analog known as acyclovir, or 9-(2-hydroxyethoxymethyl) guanosine (Figure 
1.1). Acyclovir was originally identified as an antiviral candidate through a drug screen in 
1974 at Burroughs Wellcome, and in 1979 Gertrude Elion discovered the mechanism by 
which acyclovir becomes activated specifically in HSV-1 infected cells with minimal 
toxicity on cells (51, 59). The first test of acyclovir on human HSV-1 disease occurred in 
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1979 when it was given to 23 cancer patients suffering from HSV-1 disease, and proved 
to be effective at reducing disease progression with very low toxicity (60, 61).  Soon 
thereafter, acyclovir was approved as the first selective treatment for HSV infections. 
Acyclovir represents the first specific HSV-1 inhibitor that was successfully developed to 
treat human disease, and quickly became the gold standard for treating HSV-1 diseases. 
Gertrude Elion was awarded the 1988 Nobel Prize in Physiology or Medicine with 
George Hitching and Sir James Black in part for her work on acyclovir. 
Acyclovir is a prodrug that requires a chemical modification inside the cell before 
it can exert any biological effect. Acyclovir is incredibly specific towards HSV-1 infected 
cells because it requires activation by HSV-1 thymidine kinase and is only incorporated 
into synthesizing DNA by HSV-1 DNA polymerase (Figure 1.2) (62). As a 2-
deoxyguanosine analogue, acyclovir is a prodrug that does not affect DNA replication 
until it is converted into acyclovir-triphosphate. This requires the sequential addition of 
3 phosphate groups in the same manner by which nucleosides are converted into 
nucleotides. Thymidine kinase is the enzyme responsible for adding the initial 
phosphate group and converting acyclovir into acyclovir-monophosphate. Acyclovir 
binds to purified HSV-1 thymidine kinase with 200 times greater affinity than it does to 
cellular thymidine kinase, and is phosphorylated three million times faster by HSV-1 
thymidine kinase (63, 64). These properties translate into 40 -100 times more acyclovir-
triphosphate getting formed in HSV-1 infected cells with very little cytotoxicity in 
uninfected cells (65). Furthermore, since the cellular thymidine kinase does not activate 
acyclovir, it remains as an inert acyclic guanosine analogue in uninfected cells. In 
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addition, acyclovir-triphosphate has greater affinity for HSV-1 DNA polymerase than 
cellular DNA polymerase, which means that acyclovir can only terminate HSV-1 DNA 
replication (66, 67). The serendipitous discovery that acyclovir had a profound affinity 
for HSV-1 factors with very little interaction with the cellular homologues was a major 
moment in the history of antiviral research, and has significantly impacted the way HSV-
1 diseases are treated to this day. 
The primary manner in which acyclovir inhibits HSV-1 DNA replication is through 
chain termination. While the nitrogen base of acyclovir is exactly the same as guanosine, 
the structure of the sugar backbone is severely altered and lacks a functional 3’-hydroxyl 
group (Figure 1). Acyclovir-triphosphate competes with other nucleotides for 
incorporation into DNA during synthesis. Once incorporated, the lack of a functional 3’-
hydroxyl group prevents the formation of a phosphodiester bond with the subsequent 
nucleotide, resulting in immediate chain termination (68). After acyclovir terminates 
DNA synthesis, HSV-1 DNA polymerase binds to termini of DNA terminated with 
acyclovir at 50 times greater affinity than it binds to normal 3’-hydroxl termini (69). As a 
result, HSV-1 polymerase is retained at acyclovir terminated termini and unable to 
function in DNA replication. Thus, acyclovir inhibits HSV-1 DNA replication through 
strand termination and by directly inhibiting HSV-1 DNA polymerase. The combination 
of these two mechanisms explains how acyclovir is a great inhibitor of HSV-1 infection 
with tremendous specificity towards HSV-1 infected cells and very little toxicity on 
normal cells. 
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Acyclovir received FDA approval under the brand name Zovirax in 1982 as an 
ointment for the treatment of HSL. Since then, Zovirax has received additional approvals 
as a capsule or tablet for oral deliver, a cream for topical delivery, and a suspension for 
intravenous delivery. Studies conducted across all formulations of acyclovir have 
produced mixed results. In multiple studies, topical treatment with a 5% acyclovir 
ointment was not effective at reducing HSL lesion size, duration, or pain when applied 5 
times per day for 4 to 5 days (70-73). Furthermore, doubling the amount of acyclovir to 
10% did not provide clinical efficacy either (74). While one study did show a shorter time 
to healing with acyclovir ointment, cumulatively, these results suggest that delivery of 
acyclovir as an ointment is ineffective (75). 
Topical creams differ greatly from ointments because they are a more aqueous 
base as opposed to a lipid, or oily, composition that characterizes ointments. When 
acyclovir was formulated as a 5% cream and applied to patients 5 times per day for 5 
days, the duration of lesions was reduced by 0.5-2 days and the time to crust formation 
was reduced by 1 day (75-77). Similar to the discrepancy seen with acyclovir ointment, 
other studies have reported no significant effect on lesion duration or healing under the 
same treatment regimen (72, 78). The reason for inconsistencies with topical treatment 
is likely multifaceted, with delivery of acyclovir into the tissue being the greatest 
concern. Modification of the topical formulation has enhanced delivery of acyclovir. 
Acyclovir penetrance is 8 times greater in an aqueous cream formulation than 
polyethylene (Zovirax ointment is a polyethylene base) (79). Also, the addition of 
propylene glycol into the formulation had a beneficial effect on acyclovir delivery (80). 
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As an alternative strategy, acyclovir delivered via a liposomal carrier demonstrated an 
enhanced efficacy for treating HSL (81). These results strongly suggest that optimal 
topical acyclovir delivery is greatly dependent on the formulation of the vehicle. Based 
on these studies, acyclovir cream has replaced acyclovir ointment as the preferred 
topical treatment for HSL.  
Oral delivery of acyclovir is commonly used as an alternative to topical 
treatment. However, a major drawback with this approach is the poor oral 
bioavailability of acyclovir. Administration of an 800 mg dose of acyclovir only yields an 
oral bioavailability between 10-20 % (82). Additionally, acyclovir has low solubility in 
water at room temperature, which prohibits the development of higher concentrations 
solutions (83). To overcome these limiting factors, frequent treatments with high 
concentrations of acyclovir are required (84). Administration of 200 mg or 400 mg of 
acyclovir 2-5 times daily for 5 days can reduce the time of HSL healing by 1 to 1.5 days, 
and alleviate pain if applied during the prodromal phase (85, 86). Additionally, 
prophylaxis treatment with oral acyclovir reduced the onset of recurrent HSL (50, 87, 
88). Based on these studies, oral Zovirax is most commonly prescribed for the treatment 
of HSL at a 400 mg dose taken 3 times daily for 5 days or a 200 mg dose taken 5 times 
daily for 5 days (29, 36, 43).     
Despite the high frequency of PHGS, there is a serious lack of properly conducted 
clinical studies performed to test the efficacy of antivirals (89). In 2008, a Cochrane 
review identified all studies of acyclovir for PHGS, and identified the 1997 study by Amir 
et al. as the only randomized controlled trial to meet their inclusion criteria (42). In this 
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study, children with PHGS received oral acyclovir at 15 mg/kg five times a day for seven 
days and experienced a shorter duration of: oral lesions (4 days vs 10 days with 
placebo), fever (1 day vs. 3 days with placebo), extraoral lesions (0 days vs. 5.5 days with 
placebo), eating difficulties (4 days vs. 7 days with placebo), drinking difficulties (3 days 
vs. 6 days with placebo), and viral shedding (1 days vs. 5 days with placebo) (90). 
Acyclovir was administered within the first 72 hours of symptoms; stressing the 
importance of using antivirals early during infection to benefit from their full effects. 
Zovirax is available for oral treatment of PHGS in children under the same dosing 
regimen used in the Amir et al study, and is currently the only antiviral treatment 
approved for treating PHGS in children (33, 43).  
 While acyclovir represents the gold standard for treating HSV diseases, the 
pharmacokinetic properties makes it a less than ideal therapeutic. Topical treatment is 
severely limited by inefficient delivery of acyclovir through the stratum corneum layer of 
the skin while oral delivery of acyclovir suffers from a very low bioavailability (79, 91). In 
addition to these drawbacks, acyclovir only has an intracellular half-life of 0.7-1 hour 
(92). These limitations necessitate very frequent administration of acyclovir, often 5 or 6 
times daily. This presents an inconvenient burden on patients and requires stringent 
adherence to the treatment regimen to ensure a successful clinical result. There have 
been a couple of different pursuits taken to overcome this limitation and improve 
treatment conditions for oral mucosal HSV-1 infections. The first strategy was 
developing compounds that retained the antiviral specificity and function of acyclovir 
but featured chemical modifications that improved solubility and/or pharmacokinetic 
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properties. The compounds penciclovir, famciclovir, and valcyclovir are all acyclic 
guanosine analogs derived from acyclovir and are discussed in more detail below. 
Importantly, all of these compounds require phosphorylation by the viral thymidine 
kinase to become functionally active, thus retaining the high specificity for HSV-1 
infected cells seen with acyclovir (83). A second strategy has been altering the delivery 
mechanism of acyclovir.   
Delivery of acyclovir in the form of a buccal tablet is a recent strategy that 
overcomes the bioavailability concerns of orally administered acyclovir. Approved in 
April 2013 for treatment of HSL under the brand name Sitavig, the buccal tablet contains 
50 mg of acyclovir and is applied on the upper gum line underneath the lip. This delivery 
system allows acyclovir to be released immediately in the vicinity of HSL disease. Since 
the tablet stays in place and can take up to 6 hours to fully dissolve, a sustained release 
of acyclovir occurs over a long period of time (93). In comparison to an oral 200 mg 
acyclovir tablet, the saliva concertation of acyclovir is more than 1,000-fold higher from 
the buccal tablet. The saliva concentration of acyclovir reaches levels significantly above 
the IC50 of HSV-1 within 30 mins of treatment and is sustained over 24 hours (94). Not 
surprisingly, the plasma levels of acyclovir were very low and delayed in response from 
the buccal tablet (94). When clinically tested, Sitavig resulted in a shorter duration of 
HSL episodes compared to placebo (5.6 days vs 6.4 days) and a reduced time to 
cessation of symptoms (3.6 days to 4.2 days) (94).    
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Penciclovir 
 Penciclovir was one of the earliest analogs derived that demonstrated an ability 
to inhibit HSV-1 infection (95). The structure of penciclovir is very similar to acyclovir, 
except the sugar moiety lacks an oxygen and features a second hydroxyl group in a 
position comparable to the 3’-hydroxyl group in deoxyguanosine (Figure 1.3). This slight 
distinction enables short strands of HSV-1 DNA containing penciclovir to get synthesized 
before being terminated. In comparison to acyclovir, penciclovir has a 100-fold 
reduction in affinity for HSV-1 DNA polymerase and has worse bioavailability (5%) (83, 
95, 96). However, penciclovir has far greater affinity for thymidine kinase than acyclovir, 
which results in a more rapid activation of penciclovir (97). The high affinity of 
penciclovir for HSV-1 thymidine kinase makes up for its reduced affinity for HSV-1 
polymerase, and as a result intracellular concentrations are similar to that of acyclovir. 
Also, penciclovir has a half-life of 7-20 hours in HSV-1 infected cells, which is a significant 
improvement compared to the 0.7-1 hr half-life of acyclovir (23, 98). Overall, the very 
poor bioavailability of penciclovir has precluded it from being used as an oral 
therapeutic. With a significantly improved intracellular half-life compared to acyclovir, 
penciclovir is a very promising antiviral as long as it can get into the cell. Since 
penciclovir cannot be administered orally in an effective manner, only topical 
application of penciclovir has been tested.   
 Treatment of recurrent HSL with a 1% penciclovir cream modestly improves 
healing time, reduces pain, and limits viral shedding (99, 100). In these studies, 
penciclovir was topically applied up to 6 times the first day, followed by application 
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every 2 hours for the next 4 days. The efficacy of 1% penciclovir cream was equivalent 
to treatment with 3% acyclovir cream. (101). Penciclovir is currently approved for the 
treatment of HSL as a 1% topical cream under the brand name Denavir, and requires 
application to lesion every 2 hour while awake for a duration of 4 days. 
  
Famciclovir  
Famciclovir is a diacetyl-6-deoxy analogue of penciclovir that successfully 
overcomes the bioavailability limitations seen with penciclovir. This prodrug of 
penciclovir features the addition of two acetyl groups that enables famciclovir to be 
absorbed following oral administration and delivered through the gastrointestinal tract 
to the liver (102). During first-pass metabolism, famciclovir is converted to penciclovir 
through deacetylation and oxidation of the purine nucleoside by aldehyde oxidase (103-
105) (Figure 1.3). These preliminary modifications occur quickly and result in an absolute 
penciclovir bioavailability of 77% (83, 104). Since famciclovir needs to be modified in the 
liver, it cannot be delivered in topical formulations  
Famciclovir is available under the brand name Famvir for the treatment of 
recurrent HSL. Early studies revealed that famciclovir given three times daily at 
concentrations of 125 mg, 250 mg, or 500 mg did not prevent the onset of HSL 
symptoms when induced with UV radiation (106). However, the size of lesions was 
reduced in a dose-dependent manner, and the 500 mg treatment reduced pain in the 
patients. This demonstrated that higher concentrations of famciclovir could be well 
tolerated and were more effective. A follow-up study found that a single dose of 1,500 
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mg famciclovir administered within the first hour of symptoms developing improved the 
median time to healing from 6.2 days to 4.4 days (107). This study set the benchmark 
for oral famciclovir treatment, and Famvir is currently approved for treating recurrent 
HSL as a single 1,500 mg dose. The efficacy and safety of famvir have not been tested on 
children, therefore it is not approved for the treatment of PHGS in children. However, if 
HGS occurs in adults, Famvir can be prescribed at 500 mg given three times per day for 7 
to 10 days (43). Famciclovir represents a significant improvement for the treatment of 
recurrent HSL because it replaces the requirement of constant treatment with a single 
effective dose. This has greatly improved the regimen burden for patients, and has 
become a more popularly prescribed medication for recurrent HSL (83). 
 
Valaciclovir 
Valaciclovir is the L-valine ester isoform of acyclovir that also requires 
phosphorylation by the HSV-1 thymidine kinase. Similar to how altering the chemical 
structure of penciclovir to famciclovir improved the compound’s bioavailability, the 
addition of a valine ester to acyclovir produced the compound valacicloivr, which has 
superior bioavailability to acycloivr. Valaciclovir gets absorbed through the intestine, 
where the valine ester is hydrolyzed from valciclovir producing acyclovir and valine (108, 
109) (Figure 1.4). This is a very quick process as acyclovir can be detected in plasma as 
early as 15 minutes after valciclovir administration (110). The overall absorption rate of 
valciclovir is 63%, which is a great improvement over the 15-21% absorption rate seen 
with acyclovir (111). Oral administration of a 1 g dose of valaciclovir three times a day 
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produced a similar level of plasma acyclovir as acyclovir given intravenously three times 
daily at a 5 or 10 mg/kg dose (82, 83, 112).   
 The efficacy of valaciclovir has been demonstrated in multiple studies. In one 
study, treatment with valaciclovir dosed at either 100 mg twice a day for a single day or 
500 mg twice a day for 3 days caused aborted lesions (lesion development is blocked at 
or before papule stage) in 44% of subjects with HSL (113). Time to healing was reduced 
to 3.1 days and pain was only associated for 1.5 days, which both represent a reduction 
in symptoms by about 50% compared to untreated individuals. An additional study used 
a higher concentration of valaciclovir, and determined that with 2,000 mg of valaciclovir 
twice a day for 1 or 2 days significantly reduced the duration of HSL disease by 1 day, 
and also reduced time to healing and time to cessation of pain (114). Interestingly, two 
days of treatment was not any more effective than a single day, underscoring that the 
efficacy of antiviral therapeutics is limited to the prodromal period when HSV-1 is 
actively replicating. Valaciclovir is available for oral treatment of HSL patience under the 
brand name Valtrex. The dosing regimen for Valtrex reflects the strategy used in the 
Spruance et al. 2003 study: two doses of 2,000 mg administered 12 hours apart for just 
a single day. The efficacy and safety of Valtrex have not been tested in children under 
the age of 12, so it cannot be used to treat PHGS in children.  
 
Docosanol 
 While the majority of HSV-1 antivirals exert their efficacy by inhibiting DNA 
replication, docosanol is a 22-carbon, aliphatic alcohol that functions as a broad 
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spectrum entry inhibitor of lipid-enveloped viruses (27, 51). The mechanism by which 
docosonal inhibits HSV-1 infection is not completely understood, but it is believed to 
hinder the interaction between viral glycoproteins and cell membrane receptors (115, 
116). Additionally, it may reduce the efficient transportation of viral capsids to the 
nucleus (96). The efficacy of docosanol as a 10% cream has been evaluated in multiple 
studies. A study conducted by Sacks et al. demonstrated that a 10% docosanol cream 
topically applied 5 times daily decreased the median time of healing by 18 hours, 
decreased the time for cessation of pain, and decreased the time for cessation of the 
ulcer stage of lesions (117). Another study found that if treatment with 10% docosanol 
cream was initiated at the prodromal phase, the time of healing can be decreased by 3 
days (118). Docosanol was approved by the FDA in 2000 as an over-the-counter 10% 
topical cream for the treatment of HSL, and is available under the brand name Abreva. 
Similar to the study performed by Sack et al., Abreva should be applied to HSL lesions 5 
times daily until it resolves or up to 10 days (43). Importantly, Abreva is the only over-
the-counter antiviral therapeutic available in the US for the treatment of HSL.   
 
Foscarnet and Cidofovir 
 Foscarnet and cidofovir are non-specific inhibitors of DNA synthesis that are 
considered second-line therapeutics for treating serious HSV-1 diseases. Foscarnet is a 
pyrophosphate analogue that directly inhibits DNA polymerases without the need for 
phosphorylation by viral or cellular thymidine kinase (51). This is useful for the 
treatment of HSV-1 strains that develop a thymidine kinase mutation as it can still 
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effectively impede viral DNA synthesis (110). However, without the need for HSV-1 
thymidine kinase, foscarnet lacks specificity towards HSV-1 infected cells and will cause 
the termination of both viral and cellular DNA synthesis. As a result, foscarnet has a high 
nephrotoxic profile, and is only used as a treatment option for recurrent HSL in cases 
where drug-resistant HSV-1 emerges in the immunocompromised population (119). 
Foscarnet must be slowly administered intravenously, and creatine clearance is 
constantly monitored to detect nephrotoxity (51, 110). Some of the common side 
effects associated with foscarnet include nausea, vomiting, diarrhea, headache, and 
renal impairment (120, 121).   
 Cidofovir is an acyclic nucleoside phosphonate analogue that requires 
phosphorylation by thymidine kinase to function as a DNA replication inhibitor. Unlike 
acyclovir, cidofovir gets phosphorylated by cellular thymidine kinase. As a result, 
cidofovir lacks specificity towards HSV-1 infected and has serious toxic side-effects 
because it can inhibit replication of normal uninfected cells (122). Further properties of 
Cidofovir that contribute to toxicity concerns include preferential localization to renal 
tissue, where concentrations are 100-times greater than other tissues, and long lasting 
metabolites that have a half-life of 17-48 hours (110, 123). Treatment of HSL with 
cidofovir is reserved for desperate situations where patients are not responding to any 
of the first-line therapeutics or foscarnet (124). Oral delivery of cidofovir is not possible 
due to its poor bioavailability, so it must be administered intravenously. Since cidofovir 
remains active in the body for a long period of time and has significant toxic side-effects, 
treatment is limited to a single 5 mg/kg dose per week (122, 125). Similar to foscarnet, 
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renal function has to be evaluated for patients receiving cidofovir. Side-effects are 
common with cidofovir treatment and include nausea, vomiting, headache, diarrhea, 
and renal impairment (120, 121).    
 
HSV-1 Infection in the Immunocompromised 
Patients that have a compromised immune system are significantly challenged in 
their ability to resolve HSV-1 infection, putting them at risk for developing a more 
devastating manifestation of HSL. Immunocompromised individuals include patients co-
infected with HIV/AIDS, receiving bone marrow replacement therapy following high 
dose chemotherapy, or receiving immunosuppressant therapy after organ 
transplantation. HSV-1 is a self-limiting disease in patients with a healthy immune 
system, and viral replication is suppressed 2 to 3 days after the onset of symptoms. 
However, the inability to mount an adequate immune response enables HSV-1 to 
replicate past the first couple of days, resulting in larger lesions that are very painful and 
persist for a significantly longer period of time. The frequency of recurrence is also 
higher in the immunocompromised, and is sometimes associated with inflammation of 
the tongue (glossitis) or papillae of the gums (papilltis). Visceral dissemination may 
occur if HSV-1 infection does not get resolved through therapeutic intervention, 
resulting in esophagitis, pneumonitis, retinal necrosis, hepatitis, or encephalitis (68, 126-
129). Herpes simplex virus encephalitis is the most perilous manifestation of HSV-1 
infection. Although the incidence is very low (1 to 2 cases per 500,000 people per year), 
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mortality will occur in over 70% of untreated cases (47, 130-132). Even with vigorous 
antiviral treatment, mortality still occurs in 20% of incidents (133).     
 
Treatment of Recurrent HSV Infection in Immunocompromised Patients 
Early administration of antiviral therapeutics is essential for managing HSV-1 
infection in the immunocompromised. Prophylactic treatment with antiviral medication 
is now common practice for patients receiving an organ transplant or bone marrow 
transfusion, and reduces the incidence of HSV-1 infection from 70% to 5-20% (134). 
Options available for prophylactic treatment include oral acyclovir at 400-800 mg 3 
times daily, oral valaciclovir at 500-1000 mg twice daily, or oral famciclovir at 500-1000 
mg twice daily (102). If recurrent HSL occurs despite prophylactic treatment, treatment 
with acyclovir, valaciclovir, or famciclovir can be followed for up to two weeks under the 
same dosing regimen (102). 
 
Drug-Resistant HSV-1 Infection 
Since the efficacy of antiviral HSV-1 drugs is dependent on the viral factors, 
thymidine kinase and DNA polymerase, drug-resistant strains can emerge if mutations 
arise in either of these genes. Drug-resistant HSV-1 strains only emerge at a 0.1-0.7% 
rate in immunocompetent patients because antiviral treatment regimens are very short 
and HSV-1 infection is resolved quickly. However, HSV-1 replication is active for a 
significantly longer period of time in immunocompromised patients and longer 
treatment regimens are needed with higher concentrations of antiviral drugs. Under 
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these circumstances, antiviral drugs exert a selective pressure and cause the emergence 
of drug-resistant HSV-1 strains.  
Drug-resistant infections occur at a rate ranging from 3.5% to 10% in patients 
with a compromised immune system (129). Numerous studies have investigated the 
prevalence of drug-resistant HSV-1 in different groups of immunocompromised 
patients. The prevalence of acyclovir-resistant infection is between 3.5% and 7% in HIV 
positive patients (135-140) and between 2.5% to 10% in patients receiving organ 
transplantation (140, 141). Patients undergoing bone marrow transplant after 
chemotherapy have drug resistant HSV-1 infection at a rate of 4.1%-10.9%, which is 
slightly higher than the other groups (126, 140, 142-147). The prevalence of resistant 
HSV-1 infection in the immunocompromised population has remained relatively stable 
(68). However, some reports show a slight upward trend, which may result from more 
thorough and frequent testing or an increase in the number of patients going through 
immune system compromising procedures (142, 143, 147-149). 
Ninety to ninety-five percent of acyclovir resistant strains collected from clinical 
isolates have mutations in the HSV-1 thymidine kinase (TK) gene (129, 145, 150, 151). 
Nearly 50% of such mutations occur as insertion or deletion of nucleotides in repetitive 
stretches of guanines or cytosines, while the remaining mutations are typically single 
nucleotide changes that occur in conserved regions of the gene (145, 150, 152-156). 
These mutations trigger resistance through three different mechanisms: (1) TK-negative: 
complete lack of TK activity; (2) TK-partial: lower activity of TK; (3) TK-altered: substrate-
specific mutant (resistant to acyclovir but not penciclovir) (129). TK-negative and TK-
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partial phentoypes that arise from acyclovir treatment are typically cross-resistant to 
penciclovir, famciclovir, and valaciclovir because those drugs also depend on thymidine 
kinase activity. With approximately 95% of thymidine kinase mutations arising as TK-
negative or TK-partial, patients are reliant on second-line therapeutics, such as foscarnet 
or cidofovir (157). In rare circumstances, resistance to acyclovir develops through a 
mutation in the HSV-1 DNA polymerase gene. Mutations are often located in the 
conserved regions of HSV-1 polymerase and disrupt recognition and binding of 
nucleotides or pyrophosphate (158). Resistance brought about in this manner is more 
difficult to treat because HSV-1 strains harboring this mutation are unresponsive to 
foscarnet (159-161).    
 
Therapeutic Management of Drug-Resistant HSV-1 Infections 
 A typical clinical strategy for treating recurrent HSL in immunocompromised 
patients is outlined in Figure 1.5. Drug resistance should be suspected if lesions do not 
demonstrate healing after 7 to 10 days of high dose oral acyclovir, valciclovir, or 
famciclovir treatment (158). Drug resistance of clinical isolates has historically been 
measured through plaque reduction assay, but recent advancements in next generation 
sequencing is leading to the development of more sensitive and faster testing (158, 162, 
163). If nonresponsive clinical isolates are verified to have a mutation in HSV-1 
thymidine kinase or DNA polymerase, patients should be switched to intravenous 
foscarnet treatment at 40 mg/kg every 8 hours. If HSL disease does not subside, 
resistance to foscarnet is suspected. In these dire situations, therapeutic options are 
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reduced to intravenous cidofovir at 5 mg/kg for 3-4 weeks or intravenous acyclovir at a 
high dose of 1.5-2.0 mg/kg per hour (158, 164-166). Cidofovir is the preferred choice of 
the two options because it has proven to be effective in these cases and there are no 
examples of viral resistance to it (125, 143, 165, 166). Significantly higher plasma levels 
of acyclovir can be obtained when it is delivered intravenously instead of orally, and 
acyclovir has a longer half-life (2-3 hours) in plasma (167, 168). This may be enough to 
overwhelm resistant HSV-1 infection in some patients, but cidofovir has the greater 
potential to treat acyclovir and foscarnet co-resistant infection.  
 
Conclusions 
 The past 50 years have seen a significant improvement in the management of 
oral mucosal HSV-1 infections through the discovery and development of highly specific 
acyclic guanosine analogues. However, resistant strains have developed in 
immunocompromised patients that are very challenging to treat and pose life-
threatening side-effects. Advances in technologies have made organ transplantation and 
bone marrow transfusion therapies for cancer patients more reliable, and as a result are 
more frequently performed. When coupled with the emergence of HIV in the late 20th 
century, our current society has a large population of immunocompromised people who 
are susceptible to recurrent HSL disease and the development of drug-resistant HSV-1 
infection.  
 Since all of the highly effective acyclic guanosine analogues require 
phosphorylation by thymidine kinase, a single mutation makes a strain resistant to all 
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first-line therapeutics. There is a legitimate demand for new drugs that can provide 
treatment for devastating drug-resistant oral mucosal HSV-1 disease. Targeting a 
different viral factor presents the same concern of resistance developing through 
selecting for a genetic mutation. A possible solution to this dilemma is identifying and 
targeting host factors that have a necessary role for HSV-1 replication. Viruses often 
utilize host factors and pathways to accomplish complex molecular functions to 
compensate for the limited genetic material they contain. It would be far more 
challenging for HSV-1 to develop resistance through mutation if an entire molecular 
pathway were inhibited.  
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Figure 1.1: Structure of Acyclovir. (Reprinted from Appelboom 1983 (61) with 
permission from Southern Medical Journal).  
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Figure 1.2: Mechanism of Action for Acyclovir. After entering the cell, acyclovir is 
converted to acyclovir-monophosphate by herpes thymidine kinase. Host factors 
subsequently add two more phosphate groups to form acyclovir-triphosphate, which is 
transported to the nucleus and incorporated into synthesizing DNA shown in the insert 
on the right. After, the 3’-terminal hydroxyl group of a preceding nucleotide gets 
cleaved (indicated by the red arrow), herpes DNA polymerase is responsible for inserting 
acyclovir-triphosphate into the growing herpes simplex DNA. Elongation of the DNA 
template is terminated because acyclovir-monophosphate lacks a 3’ hydroxyl group. 
(Reproduced with permission from Balfour 1999 (62), Copyright Massachusetts Medical 
Society). 
 
 
32 
 
 
 
Figure 1.3: Conversion of Famciclovir into Penciclovir. (Reprinted from De Clercq 2006 
(83) with permission from British Journal of Pharmacology). 
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Figure 1.4: Conversion of Valaciclovir into Acyclovir. (Reprinted from De Clercq 2006 
(83) with permission from British Journal of Pharmacology).  
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Figure 1.5: Management of HSL Nonresponsive to First-line Therapeutics in 
Immunocompromised Patients. (Reprinted from Piret 2011 (129) with permission from 
ASM).  
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Chapter 2: HSV-1 Infection and the Role of the DNA Damage Response 
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HSV-1 Virion Structure 
 The herpesvirus virion is a spherical particle 186 nm in diameter with spikes on 
its surface that extend the diameter to 225 nm (169). The virion is composed of four 
distinct structures: a core, capsid, tegument, and an envelope (170). The core contains 
the double stranded viral DNA, which exists in a liquid crystalline state (171, 172). DNA 
packaged in the virion lacks histones or any other basic proteins to neutralize the 
negative phosphate charges. Instead, there are 70,000 molecules of spermine and 
40,000 molecules of spermidine within the core that very tightly bind the DNA, causing 
40% of the DNA phosphate groups to be neutralized; this results in shaping the DNA into 
a toroidal structure (173, 174). 
The capsid is composed of 162 capsomeres (140 hexons, 11 pentons, and 1 
portal capsomeres) that are arranged in a T = 16 icosahedral structure (170, 175). There 
are four viral proteins primarily responsible for forming the capsomeres: VP5 (UL19), 
VP26 (UL35), VP23 (UL18), and VP19C (UL38). VP5 proteins combine in groups of five to 
form penton capsomeres and groups of six to form hexon capsomeres. The capsomeres 
are linked together through VP26, VP19C, and VP23. In addition, the viral factor UL6 
forms a portal that is essential for DNA packaging (170).  
Surrounding the capsid is the tegument layer, which contains at least 23 viral 
proteins and some cellular proteins. Tegument factors are further classified as inner 
tegument and outer tegument proteins based on their propensity for association with 
the capsid or envelope (176). The tegument serves multiple functions that are essential 
for productive HSV-1 infection. These include: stabilizing the virion by connecting the 
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capsid to the membrane; assisting in the delivery of the capsid to the host nucleus 
through modulation of cellular factors; and coating progeny capsids in the cytoplasm to 
assist with virion maturation and secondary envelopment (177). 
The envelope is the outer layer of the HSV virion and consists of a lipid bilayer 
containing 11 viral glycoproteins (gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL, and gM) and 
additional nonglycosylated viral proteins (UL20, US9) (170). The envelope is formed 
during secondary envelopment with trans-Golgi network derived vesicles that contain 
viral glycoproteins (177, 178). Structurally, the glycoproteins form spikes that extend 
from the envelope and can be detected by electron microscopy (169, 179). The 
glycoproteins are recognized by cellular receptors, and these interactions are vital for 
entry of the virion into the cell (180).   
 
HSV-1 Genome Architecture 
 HSV-1 has a double stranded DNA genome 152 kb in size with a G + C 
composition of 68%, and codes for 84 genes (181-183). The genome is packaged into the 
virion as a linear structure, but the terminal ends join together to form a circular 
structure upon infection. Structurally, the genome is composed of two sections 
designated L (long) and S (short) (184). Each section contains a long stretch of DNA with 
a unique sequence (UL or US, respectively) that is flanked by a sequence of repetitive 
DNA (Figure 2.1). The repetitive regions flanking each section are inverted repeats of 
each other. Interestingly, the periphery of the repetitive regions for both the L and S 
sections have the same exact DNA sequence called the a region. This feature enables 
38 
 
recombination between the L and S sections during HSV-1 infection. As a result, four 
different orientations of the unique sequences arise at equimolar concentrations.  
There are also regions of unique and repetitive sequences within the a sequence, 
and the overall structure is designated: DR1-Ub-DR2n-DR4m-Uc-DR1 (185, 186). On both 
ends of the a sequence is a 20bp direct repeat (DR1), followed internally by a unique 
sequence (Ub and Uc), and two more repetitive regions (DR2n and DR4m). Ub is a 65 bp 
sequence and Uc is a 58bp sequence. DR2n is a 12 bp direct repeat of which there are 
between 19 and 23 copies. DR4m is a 37 bp direct repeat present in 2 to 3 copies. On the 
terminal ends of the linear HSV-1 genome, the DR1 sections of the a regions are 
incomplete. On the L section, the DR1 is only 18bp, while the DR1 on the S section is 
only 1 bp (186). When the ends circularize, the incomplete DR1 sections join together to 
form a complete DR1 sequence (170).  
 
Lytic Infection 
Entry  
Entry of the HSV-1 virion into the host cell requires direct binding to cellular 
receptors and fusion of the envelope with the cell membrane. The first step for 
successful entry is the recognition and binding of the virion to the appropriate cell type. 
This is facilitated by the viral glycoprotein D (gD), which binds to one of two cellular 
receptors, Nectin-1 or HVEM (187). Nectin-1 is found on epithelial and neuronal cells 
and functions as a cell adhesion molecule, while HVEM is a TNFR-like receptor found on 
immune cells (188, 189). Since HSV-1 infections occur in epithelial cells before 
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establishing latency in neurons, the affinity of gD for Nectin-1 makes logical sense and is 
the preferred target (188, 190). However, it is still not completely understood why gD 
binds to HVEM because HSV-1 cannot infect T-cells. It has been proposed that this 
interaction may disrupt the immune system, enabling infection to occur (191, 192). 
Direct binding between the virion and cell can be augmented through binding of 
glycoprotein C (gC) with heparan sulfate, which is a glycosaminoglycan found on the 
majority of cells. While the interaction between gC and heparan sulfate enhances 
infectivity, it is not essential for viral entry (180).  
 Fusion between the virion and cellular membrane is the next step required for 
entry. The virion envelope is equipped with glycoproteins gH, gL, and gB that form the 
core fusion machinery. gH and gL are highly conserved herpesvirus proteins that exist as 
a heterodimer in the virion envelope, while gB is the viral factor that catalytically fuses 
the virion envelope to the cell membrane (193). After gD binds to its cellular receptor, a 
conformational change occurs that enables binding of gH/gL to gB, and brings the virion 
envelope and cell membrane in closer proximity (194). The interaction between gH/gL 
and gB also enhances the activity of gB, which fuses the two membranes together 
through its fusion loop domains (195). Fusion of the cellular membrane with the virion 
envelope enables delivery of the capsid and tegument into the cell and marks the 
completion of entry.  
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Nuclear Events 
The capsid travels along microtubules in a dynein-dependent manner to the 
nucleus and docks on the nuclear pore complex (NPC) (196, 197). The factors 
responsible for binding the capsid to the NPC have not been identified, but a tegument 
factor(s) is likely involved (198). Viral DNA is packaged inside the virion core with an 
internal pressure of tens of atmosphere, so when the virion is uncoated, the DNA is 
ejected through a pressure driven release and translocates the nuclear pore (199).  
When HSV-1 DNA enters the nucleus, it is immediately recognized as a threat, 
and the cell responds by mobilizing countermeasures that attempt to silence viral gene 
expression and replication. A main defensive strategy is to silence viral gene expression 
and genome replication by packaging the foreign DNA into a highly condensed 
heterochromatin state (200, 201). Upon entering the nucleus, the invading HSV-1 DNA is 
rapidly associated with histones bearing modifications associated with heterochromatin 
that recruit transcription repressing complexes, such as the CoRest-HDAC complex (202-
205) . Furthermore, the viral genome localizes near ND10 bodies, which are nuclear 
substructures that contain PML, Sp100, hDaxx, and ATRX that restrict expression of viral 
immediate early genes (200, 206).  
HSV-1 is equipped with ways to overcome each of these limitations to achieve 
productive infection. Repressive histone modifications are reversed through the 
recruitment of the LSD1 and JMJD2 histone demethylases, which allows transcription of 
viral immediate early genes (205, 207-210). The viral factor ICP0 is an immediate early 
factor that functions as an E3 ubquitin ligase (211). As a member of the tegument, it is 
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present in the cell during the initial phases of infection and disrupts the antiviral 
function of ND10 bodies by targeting PML and Sp100 for degradation and preventing 
hDaxx and ATRX association with HSV-1 DNA (211-217). Additionally, ICP0 dissociates 
HDACs from the CoREST/REST complex (203, 218). With the removal of these chromatin 
modifying factors, the viral genome becomes accessible for viral gene expression and 
DNA replication.  
Viral genes are classified into one of three groups: immediate early (IE), early (E), 
and late (L) (219, 220). The classification of a gene into a particular group is largely 
dependent on when it is expressed during the lytic life cycle, but also depends on its 
function (Figure 2.2). The IE genes are the first group to be expressed, and consist of 6 
genes: ICP0, ICP4, ICP22, ICP27, Us1.5, and ICP47 (170). A key characteristic of these 
genes is that their expression occurs without de novo synthesis of additional viral 
factors. Transcription of these genes is simulated through the utilization of host factors. 
The tegument component, VP16, forms a protein complex with cellular proteins host 
cell factor 1 (HCF-1) and octamer-binding transcription factor 1 (Oct-1) that recognizes 
the consensus sequence (ATGCTAATGARATTCTTT) located in the response element 
located in the enhancer region of each IE gene (208). Expression is further enhanced 
through the involvement of cellular transcription factors GABP and Sp1 (221-223). 
 The main function of the IE factors is to transcribe E genes through direct and 
indirect processes. Of the IE genes, ICP0 is best characterized, and functions to indirectly 
promote E expression by modulating the cellular environment. As an E3 ubquitin ligase, 
ICP0 targets numerous cellular factors and marks them for proteasomal degradation. As 
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previously mentioned, a major function of ICP0 to subvert the intrinsic antiviral defense 
of the host cell, and it accomplishes this by removing repressive chromatin factors from 
the viral genome. Additionally, ICP0 alters the DNA damage response, inhibits the 
interferon response, and regulates latency (224). ICP4 binds directly to the HSV-1 
genome and, through its direct interaction with TFIID and the mediator complex, 
functions as a major transactivator of HSV-1 E and L gene expression (225). Unlike ICP0 
and ICP4, the other IE genes are nonessential for HSV-1 replication, but have important 
functions for accomplishing a highly productive infection. ICP27 has a role in preventing 
synthesis of cellular proteins by inhibiting the splicing of host mRNAs (226-228), and it 
can recruit RNA polymerase II (RNA Pol II) to E genes to promote transcription (229). 
ICP22 and ICP47 are not as well characterized as the other IE factors; ICP22 appears to 
have a role in enhancing viral gene expression by interacting with RNA Pol II (230-232), 
while ICP47 has a role in inhibiting the immune response by preventing proper antigen 
presentation on MHC class I molecules (233).   
 The E genes are most recognized for coding proteins involved in DNA replication 
of the HSV-1 genome. There are seven essential replication factors: an origin-binding 
protein (UL9), single-strand binding protein (ICP8, also known as UL29), a two subunit 
DNA polymerase (UL30 and UL42), and a three subunit helicase/primase complex (UL5, 
UL8, and UL52) (234). There are three replication origins in the HSV-1 genome: two 
copies of OriS, located in the repeat region of the genome, and OriL, located in the UL 
region (235). Replication begins with UL9 and ICP8 opening at least one of the origins of 
replication. The recruitment of HSV-1 helicase/primase and DNA polymerase causes the 
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DNA to unwind and DNA synthesis to proceed. Since the viral genome circularizes soon 
after entering the nucleus, replication of the viral genome is predominantly believed to 
occur in a theta manner before converting to rolling circle (236, 237). Replication by 
rolling circle produces long head-to-tail concatemers that must be properly cleaved 
during encapsulation to ensure a single genomic copy is incorporated in each capsid 
(238).  
The last group of viral genes to be expressed is the L genes, which code for 
structural proteins involved in capsid and envelope development (219). The L genes can 
be further classified into two subgroups: leaky late and true late. The difference 
between leaky and true late genes is the reliance on HSV-1 DNA replication. The true 
late genes can only be expressed when HSV-1 DNA is actively replicating, whereas the 
leaky late genes can be expressed when HSV-1 DNA replication is pharmacologically 
inhibited. It is not fully understood what determines whether a late gene will be reliant 
on genome replication, but one possible explanation is that the incoming viral genome 
cannot act as a template for true late gene expression (239, 240). The L genes code for 
the structural components, capsid proteins and glycoproteins, and tegument factors. 
The production of L genes in conjunction with a high level of newly synthesized HSV-1 
genomes, allows the formation of virions to proceed. 
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Virion Maturation 
Virion maturation occurs through four major steps: packaging viral DNA into 
capsids, transport out of the nucleus (primary envelopment and de-envelopment), 
formation of the tegument layer with secondary envelopment, and exit from the cell 
through exocytosis or cell-to-cell spread (Figure 2.3)(177). Packaging of nascent viral 
DNA into capsids occurs in the nucleus. The L terminal gets loaded into capsids through 
an ATP-dependent process (241, 242). Located at the capsid portal is the terminase 
complex (composed of three subunits; UL15, UL28, UL33) that recognizes a packaging 
sequence in the a sequence and cleaves the concatemeric DNA, ensuring that one copy 
of the HSV-1 genome gets encapsidated (243, 244). 
The next step in virion maturation involves egress of the packaged capsid out of 
the nucleus through an envelopment and de-envelopment process. Viral factors loosen 
the lamina structure allowing virions to merge into the inner nuclear membrane (189, 
245). Virions become enveloped with the inner nuclear membrane and transport though 
the inner nuclear membrane space until they reach the outer nuclear membrane (243, 
246). At this juncture, the inner nuclear membrane surrounding the capsid buds into the 
outer nuclear membrane, releasing the virion into the cytoplasm free of any envelope 
(243). 
After the capsid egresses out of the nucleus, it gets covered with viral and 
cellular factors that become the inner tegument within the mature virion (247). Viral 
glycoproteins are synthesized during these initial steps of virion maturation and are 
processed through the trans-golgi network (TGN) (248-250). Vesicles that contain viral 
45 
 
glycoproteins with their C-terminal portion exposed to the cytoplasm are secreted from 
the TGN (251, 252). Additional viral factors that will become the outer tegument layer of 
the mature virion particle associate on the C-terminal portion of the glyocproteins and 
outer surface of the vesicle membrane (176). Capsids containing the inner tegument 
layer bind to the exposed surface of these vesicles and become enveloped with their 
membrane (177, 253, 254). This results in the complete formation of a fully mature 
virion particle contained within a vesicle (255-258). The mature virions are transported 
to the cellular plasma membrane by cellular trafficking factors such as Rab6a, Rab8am 
Rab11a, GAP-43, kinesin-1m SNAP-25, and protein kinase D (259-262). Virions can either 
be released into the extracellular space where they can infect other cells by binding to 
surface receptors, or they can infect neighboring cells through cell-to-cell contact. 
 
Latency 
 In addition to infecting neighboring epithelial cells, released virions can infect 
sensory neurons that are innervated in the epithelium. Infection of neighboring sensory 
neurons is the first step for establishing latency (Figure 2.4)(177). Upon neuron 
entrance, the capsid is transported to the cell body of the neuron where the viral DNA is 
ejected into the nucleus and circularizes. Unlike in epithelial cells, expression of viral 
factors does not proceed. Instead, the HSV-1 genome is packaged into an inaccessible 
heterochromatin state through the modification of histones and recruitment of 
chromatin scaffolding factors, such as the repressor element silencing transcription 
(REST) factor (263-267). This prevents the expression of all viral transcripts expect for 
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the latency associated transcript (LAT) (268, 269). This non-coding RNA transcripts is 
essential for maintaining latency by assembling heterochromatin on lytic genes, 
protecting neurons from apoptosis, and evading the immune system response (265, 
270-273). HSV-1 establishes life-long infection in the neuronal environment, but is also 
subject to reactivation in response to the physiological stressors (discussed in Chapter 
1). During reactivation, a small number of virion progeny are produced and travel in an 
anterograde direction back to the oral mucosal epithelium where it initiates a new 
round of lytic infection (274). 
 
Mammalian DNA Damage Response 
The DNA damage response (DDR) is a complex intracellular network of factors 
designed to maintain the integrity of the cellular genome. It has been estimated that 
104-105 spontaneous DNA lesions occur on a daily basis due to endogenous and 
exogenous sources of DNA damage (275). Deamination, depurination, alkylation, and 
oxidation of DNA bases can occur spontaneously as a result of cellular metabolism, 
whereas environmental sources can cause both physical and chemical alterations of 
DNA. Some common exogenous sources of DNA damage include: ionizing radiation (IR), 
ultraviolet (UV) light, cigarette smoke, and many drugs used in cancer chemotherapy 
(DNA alkylating agents: methyl methanesulfonate, temozolomide; crosslinking agents, 
e.g. mitomycin C, cisplatin, psoralen; and topoisomerase inhibitors, e.g. camptothecin, 
etoposide (276).  
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 The myriad of damaging agents gives rise to a variety of DNA lesions; some more 
deleterious to the cell than others. While endogenous DNA damage sources tend to 
cause chemical alteration of DNA bases, exogenous DNA damage sources can cause 
pyrimidine dimers, intra-strand crosslinks, inter-strand crosslinks, single strand DNA 
(ssDNA) breaks, and double strand DNA breaks (DSB). The cellular DDR is equipped with 
numerous mechanisms to repair each type of insult. For example, mismatch repair 
(MMR) fixes incorrectly paired DNA bases, base excision repair (BER) removes 
chemically altered DNA bases, and nucleotide excision repair (NER) corrects larger 
lesions, such as pyrimidine dimers and intra-strand crosslinks (277).  
 The most threatening form of DNA damage is DSBs, which can lead to cell death 
if not properly repaired. The cell is equipped with two different mechanisms to repair 
DBSs: nonhomologous end joining (NHEJ) and homologous recombination (HR). Both 
repair pathways have the ability to sense DSBs and utilize a sensor kinase that 
orchestrates DNA repair by modulating the chromatin landscape surrounding the break 
site and recruiting repair factors.   
The default method for repairing DSBs is the NHEJ pathway, which occurs when 
exposed DNA ends are recognized and tethered together by the Ku70 and Ku80 
heterodimer (278, 279). The sensor kinase responsible for coordinating NHEJ repair is 
DNA-dependent Protein Kinase (DNA-PK). Free DNA ends bound by Ku70 and Ku80 
recruit the catalytic sub-unit of DNA-PK (DNA-PKcs), and together these subunits form 
DNA-PK (276). Once associated with DNA, DNA-PKcs becomes catalytically active leading 
to phosphorylation of itself and phosphorylation of many NHEJ repair factors, including: 
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Ku70, Ku80, XRCC4, XLF, Artemis, and DNA ligase IV (280-285). Artemis is a 5’ to 3’ 
exonuclease that is recruited next and removes any nucleotides that would prevent 
direct ligation of the DNA ends. DNA-PKcs and Artemis then dissociate from the break 
site as XRCC4, XLF, and DNA Ligase IV are recruited. XRCC4 is a nonenzymatic protein 
that binds to DNA Ligase IV and also forms long helical filaments with XLF (286). This 
filamentous structure has a strong affinity for DNA at break sites, resulting in the 
recruitment of DNA Ligase IV to the break site and culminating in the ligation and repair 
of the DSB (287, 288).  
Repair of DSB by HR ensures that the damaged region of DNA is completely 
restored to its original sequence. Since NHEJ ligates the free ends together with no 
method of restoring lost base pairs, the repair process generally results in a loss of 
genetic information. However, HR uses a sister chromatid as a template to resynthesize 
the damaged portion of DNA. This highly effective process ensures that the sequence of 
damaged DNA is fully restored and prevents the loss of genetic material. The need for a 
sister chromatid mandates that HR can only occur during S or G2 phases of the cell cycle 
when homologous copies are present. 
The first step in HR is sensing the free DNA ends that result from a DSB. The 
proteins Mre11, Rad50, and Nbs1 form the tripartite complex MRN, and very quickly 
associate with a DSB (289-291). Multiple functions are carried out by MRN, including 
resection of DNA ends through the endonuclease activity of Mre11 and the recruitment 
of Ataxia Telangiectasia Mutated (ATM) through direct binding with Nbs1 (292). ATM is 
the pivotal sensor kinase that coordinates this branch of the DDR response. ATM 
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phosphorylates proteins on a consensus SQ/TQ amino acid motif, and has hundreds of 
substrates within the cell (293-296). ATM is essential for initiating HR repair by 
recruiting repair factors to the break site that optimize the chromatin landscape and 
cause resection of DNA ends.  
Immediately after being recruited by MRN, ATM phosphorylates the histone 
variant, H2AX, on serine 139, commonly referred to as γH2AX (Figure 2.5)(297). This 
post-translational modification alters the chromatin landscape and unleashes a cascade 
of repair factor recruitment. First, mediator of DNA damage checkpoint 1 (MDC1) binds 
to γH2AX, and an additional copy of MRN associates at the break site by binding directly 
to MDC1 (298-300). This subsequently recruits another ATM kinase, which 
phosphorylates the adjacent H2AX histone (301, 302). This establishes a repetitive 
sequence of events that results in the spread of H2AX phosphorylation along the 
chromatin on either side of the DSB (297). In fact, γH2AX phosphorylation can extend up 
to 2 megabases from the DSB since H2AX variants are located, on average, every fifth 
nucleosome (303, 304). Additional factors are recruited during this process, including 
the ligases RNF8 and RNF168 that produce a K63 ubiquitin chain on H2A and γH2AX 
which tethers BRCA1 (305-307).  
Modification of the chromatin landscape is important for optimizing the 
damaged DNA for repair by HR. Another vital step before HR can proceed is resection of 
the exposed DNA ends to create ssDNA that can synthesize new DNA from a 
homologous DNA template. The exonucleases CtIP and Exo1 are regulated by ATM and 
remove DNA from the free DNA ends, resulting in long stretches of ssDNA (308-311). 
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RPA32 is a ssDNA binding protein that immediately coats the exposed ssDNA to protect 
it from further damage (312). Ultimately, RPA32 gets displaced and substituted with 
Rad51 in a BRCA2-dependent manner (289, 312, 313). This creates long Rad51 filaments 
that have stand invasion capabilities essential for initiating HR (314-316).  
The DDR mediated by ATM signaling is highly versatile and features mechanisms 
to repair DSBs in difficult chromatin landscapes. Heterochromatin poses a major 
challenge for the recruitment of large networks of proteins. The DDR is equipped with 
ways to loosen the chromatin landscape, allowing proper access of repair factors to the 
break site. Kap1 is a scaffolding protein that interacts with HP-1 and CHD3 to maintain 
heterochromatin (317). In response to DNA damage, ATM phosphorylates Kap1 on 
serine 824. This induces a conformational change in Kap1 that disrupts the interaction 
between Kap1 and CHD3, causing a loosening of the heterochromatin architecture and 
enabling access of repair factors to the DSB (318). While Kap1 gets phosphorylated by 
ATM in a robust pan nuclear manner in response to DNA damaging agents, this 
modification is only functionally required for the repair of DSBs in heterochromatin 
(319).   
In addition to ATM and DNA-PKcs, there is a third PI3K-like kinase involved in the 
DDR, Ataxia Telangiectasia and Rad3-related (ATR). The main function of ATR is to 
respond to ssDNA. ATR is recruited to RPA coated ssDNA through its interacting partner 
ATRIP (320). This normally occurs when DNA replication is stalled for an extended period 
of time. ATR recruitment also occurs during the later stages of HR repair due to the 
presence of long, exposed ssDNA (321). Downstream targets of ATR are factors that 
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induce a replication checkpoint, such as Chk1, MCM proteins, RPA, DNA polymerase, 
and Clapsin (322).   
In order to properly repair DNA lesions and prevent further damage from 
occurring, the DDR is heavily involved in regulating the cell cycle. ATM phosphorylates 
Checkpoint Kinase 2 (Chk2) on threonine 68 inducing a conformational change that 
results in Chk2 dimerization and formation of an active kinase domain (323, 324). A 
major function of Chk2 is to stall the cell cycle at either the G1/S checkpoint or the 
G2/M checkpoints (325). Chk2 phosphorylation of the phosphatase Cdc25A causes it to 
be degraded, which prevents the activation of cyclin-dependent kinase 2 and keeps the 
cell stalled at the G1/S checkpoint (326). Additionally, the transcriptional activity of p53 
is upregulated through phosphorylation by both ATM and Chk2, resulting in the 
expression of p21, which functions to maintain the G1/S arrest (327). Stalling the cell 
cycle at G2/M happens in a similar way with Chk2 phosphorylating Cdc25C, causing it to 
be translocated into the cytoplasm where it is inactive and cannot activate the 
cyclinB1/Cdk1 complex (328, 329).  
In the event that DNA damage cannot be resolved by repair, the DDR initiates 
apoptosis. A major factor in controlling apoptosis is p53. As mentioned above, ATM and 
Chk2 can phosphorylate p53 to activate its transcriptional activity and many of its 
targets are pro-apoptotic factors (Fas-R, Bax, Puma, Noxa, Apaf-1, and Pidd) (330, 331). 
ATM signaling can also activate another transcription factor, NK-κB, which upregulates 
the pro-apoptotic factors Bcl-xL, A1/Bfl-1, c-IAPs, and TrAF 1 and 2 (331, 332). Many of 
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these downstream factors proceed to disrupt mitochondrial potential and activate the 
caspase cascade involved in carrying out apoptosis.     
 
Interaction Between HSV-1 and the DDR 
Viruses are limited life-forms that require entry into a host cell for replication. 
This parasitic nature of viruses manifests through the manipulation of cellular pathways 
in a way that establishes productive infection. The DNA damage response is a cellular 
pathway frequently targeted by viruses due to its multifaceted function in regulating 
genome integrity and controlling cellular homeostasis; however, the versatile nature of 
the DDR can be both beneficial and detrimental to viral replication (333-335). Through 
evolution, viruses have become equipped with ways to circumvent the repressive 
aspects of the DDR while benefiting from utilizing other aspects. The way in which the 
DDR is manipulated is unique to each virus, reflecting the diverse ways in which viruses 
infiltrate the host cell (334). 
Growing evidence suggests that the DDR can function in the intrinsic antiviral 
response. Unwanted manipulation of the viral genome by repair pathways can have an 
inhibitory effect on DNA replication. HSV-1 counteracts these repressive events 
predominantly through the function of ICP0, which ubiquitinates host factors to target 
them for degradation (217). The NHEJ repair pathway is inhibitory for HSV-1 replication, 
and HSV-1 overcomes this barrier through ICP0-mediated degradation of DNA-PKcs, 
which happens early during infection (212, 217, 336). Additionally, ICP0 redistributes 
ATRIP away from ATR, which cripples the signaling activity of this major repair pathway 
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(337). Another intrinsic antiviral component are ND10 structures, which are depots of 
chromatin and DDR factors that localize near incoming HSV-1 DNA and attempt to 
suppress the viral genome. ICP0 targets components of ND10 structures, such as PML 
and Sp100, for degradation, thus disrupting the antiviral function of ND10 (212, 213).  
Utilization of the host DDR can also be beneficial for viruses because it provides 
the ability to perform highly intricate functions that could not be accomplished through 
viral products alone. It has been reported by multiple groups that HSV-1 infection 
causes the activation of ATM (338-341). This has been demonstrated by 
autophosphorylation of ATM and phosphorylation of many ATM targets, including 
H2AX, Nbs1, 53BP1, p53, Sp1, and Chk2. Interestingly, all of these DDR factors co-
localize at HSV-1 replication compartments (RC), which are nuclear structures depicting 
active HSV-1 DNA replication (338-343). This suggests that the ATM-mediated DDR has a 
role in replication of the HSV-1 genome. HSV-1 replication is significantly suppressed in 
cells lacking functional Mre11 or ATM, demonstrating that ATM signaling is required for 
HSV-1 infection (338). Furthermore, inhibition of ATM or Chk2 with small molecule 
inhibitors greatly reduces HSV-1 infection in models of herpes keratitis (341, 342). It has 
become evident that the ATM branch of the DDR has an essential role in HSV-1 
infection, and is not a bystander effect of infection. 
In addition to modulating repair factors, ATM signaling may have an essential 
role in controlling the cell cycle during HSV-1 infection. It is well established that HSV-1 
stalls the cell cycle at the G1/S checkpoint (344-347). This checkpoint arrest can prevent 
progression of cells out of a G0 quiescent state, and can halt actively replicating cells 
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form progressing forward (344). The cell cycle can also be blocked at the G2/M 
checkpoint (348, 349). Interestingly, both p53 and Chk2 are involved in achieving these 
checkpoint arrests (348, 349). Although the role of ATM in establishing these HSV-1 
induced cell cycle arrests has not been investigated, both p53 and Chk2 are well 
characterized targets of ATM that cause the same cell cycle arrest in response to DNA 
damage.  
Successful HSV-1 infection also has to navigate the apoptotic response. 
Apoptosis is a programmed method of cellular suicide that can function as an escape 
mechanism when cells are infected with virus (350). HSV-1 infection triggers apoptosis 
independently of de novo synthesis through expression of the ICP0 transcript (351-357). 
In order for HSV-1 infection to be successful, apoptosis must be suppressed so that the 
cell can remain functional long enough for viral progeny to be produced. The expression 
of a viral factor(s) between 3 to 6 hours after infection is capable of suppressing the 
apoptotic response (352, 358). Several viral factors have been implicated for having anti-
apoptotic function: ICP4, ICP27, ICP22, LAT, gD, gJ, UL14, Us11, and Us3 (359-368). 
While the mechanism of apoptotic induction and suppression is not completely 
understood, it appears that the same cellular factors commonly employed for inducing 
apoptosis in response to DNA damage are utilized during HSV-1 infection, particularly 
NF-κB and p53 (369-371). It remains to be determined if the initial induction of 
apoptosis has any beneficial effects for early viral events. The methods that are used to 
suppress apoptosis likely involve manipulation of downstream factors in the DNA 
damage response.       
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It is commonly stated that HSV-1 activates the ATM pathway while abrogating 
the ATR and DNA-PKcs pathways, however this does not accurately describe the cellular 
environment created during HSV-1 infection. Despite ATR inactivation, many factors 
associated with the ATR signaling pathway are associated with HSV-1 RC and are 
required for HSV-1 replication (372, 373). Also, it has been reported that the NHEJ 
factors, XRCC4 and DNA Ligase IV, are required for productive HSV-1 infection, even 
though DNA-PKcs gets degraded (374). Furthermore activation of the ATM signaling 
pathway is coupled with degradation of RNF8 and RNF168 by ICP0, which specifically 
terminates the ATM-mediated signaling cascade and prevents the recruitment of 
downstream factors involved in HR (375-377). While it is evident that the recruitment 
and utilization of upstream factors in the ATM pathway are necessary, it remains to be 
seen how disruption of RNF8 and RNF168 impacts their function. All of these 
observations suggest that HSV-1 utilizes the DDR in a specialized manner that is unique 
to the environment it creates. It remains possible that repair factors are used by HSV-1 
in ways that have not been previously considered. 
  
Conclusion 
In summary, there is a complex relationship between HSV-1 and the cellular 
host. The versatile DNA damage response is used both by the cell as an intrinsic defense 
mechanism and by the virus to facilitate unknown functions needed for productive 
infection. Further research into the interaction between HSV-1 and the host DDR will 
unveil unknown properties about HSV-1 that may also pertain to other viruses.   
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As mentioned in Chapter 1, combatting drug-resistant strains of HSV-1 is a major 
clinical challenge that requires new therapeutic options. Targeting critical factors in the 
DDR is a promising approach for multiple reasons. Drug-resistant strains all feature 
mutations in either HSV-1 thymidine kinase or HSV-1 DNA polymerase. Inhibitors 
targeting cellular DDR factors will not be impacted by mutations in these viral genes, 
and will maintain their efficacy. Furthermore, the development of resistant strains 
would be significantly more unlikely using an inhibitor against the DDR. As mentioned 
earlier in this chapter, ATM targets a multitude of DDR factors and regulates numerous 
pathways within the cell. It is highly likely that multiple functions downstream of ATM 
signaling are utilized by HSV-1. In this case, it would be drastically more difficult to 
induce a mutant strain of HSV-1 that can compensate for every manner in which ATM is 
used.  
Our lab has previously demonstrated that the ATM inhibitor, KU-55933, and the 
Chk2 inhibitor, Chk2 Inhibitor II, are both effective at suppressing HSV-1 replication in 
models of herpes simplex keratitis (341, 342). The work presented herein expands upon 
these findings and demonstrates the efficacy of these inhibitors for the treatment of 
oral mucosal HSV-1 infections.  
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Figure 2.1: Architecture of the HSV-1 Genome. (A) The HSV-1 genome is composed of 
the long (L) and short (S) sections that each have long stretches of unique DNA 
sequences (I) and (s) respectively flanked by repetitive sequences of DNA (long section: 
ab and b’a’; short section: a’c’ and ca). (B) Four isomers of HSV-1 genomes. Orientation 
of long and short sections inverts relative to the repetitive sequences. 
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Figure 2.2: Lytic HSV-1 infection in an Oral Mucosal Cell. HSV-1 enters cell releasing 
tegument into the cytoplasm as the capsid travels to the nuclear membrane. HSV-1 DNA 
is ejected out of the capsid into the nucleus and initiates a cascade of viral transcription. 
First, the immediate early (IE) genes get expressed which facilitate the expression of 
early (E) and late (L) genes. Early genes code for factors required for viral genome 
replication. Late genes code for structural factors used for constructing the capsid and 
envelope. Virion maturation occurs, which involves: nucleocapsid egress out of the 
nucleus, coating with tegument, acquisition of an envelope, and egress out of the cell.  
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Figure 2.3: Virion Maturation. (1) Viral DNA is loaded into newly assembled capsids. (2) 
Capsids egress out of the nucleus through a primary envelopment & de-envelopment 
process (3) Capsids become coated with tegument factors and acquire an envelope by 
binding to glycoproteins located on vesicles produced from the TGN/endosome. (4) Fully 
matured virions exit the cell through exocytosis or cell-to-cell spread. (Reprinted from 
Owen et al. 2015 (177), open access). 
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Figure 2.4: Establishment of Latency. Virions released from epithelial cells infect 
sensory neurons. Retrograde transport of capsids to the neuronal cell body occurs 
through dynein. HSV-1 genome establishes latency in the cell body, but will reactivate in 
response to physiological stressors. Reactivated HSV-1 replicates at a low level in the 
neuronal cell body. Progeny virus undergoes anterograde delivery through kinesin back 
to epithelial cells. (Reprinted from Owen et al. 2015 (177), open access). 
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Figure 2.5: ATM DNA Damage Response. (A) DNA damage induces a DSB (B) The MRN 
complex recognizes the exposed DNA at the break site and recruits ATM. ATM 
phosphorylates H2AX, which leads to MDC1 recruitments. MDC1 gets phosphorylated 
by CK2, leading to MRN recruitment. ATM is recruited by MRN and phosphorylates 
MDC1 as well as adjacent H2AX, establishing a repetitive sequence of events. H2AX is 
also acetylated by TIP60 and ubiquitinated by UBC13 (C) RNF8 is recruited to MDC1 and 
ubiquitinates H2AX leading to RNF168 recruitment. RNF168 produces a 
polyubiquitnated track on histone H2AX that is necessary for BRCA1 recruitment. (D) 
This response produces DSB repair and cell cycle arrest. (Reprinted with permission 
from Attikum and Gasser 2009 (297)).  
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Chapter 3: Inhibition of ATM or Chk2 Suppresses Oral Mucosal HSV-1 Infection 
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Introduction 
 HSV-1 infection is extremely prevalent worldwide and most frequently manifests 
in the oral mucosa as herpes simplex labialis. Up to 10% of patients with a compromised 
immune system will develop drug-resistant HSV-1 infection. Treatment options for these 
individuals are limited to nonspecific and highly toxic second-line drugs, such as 
foscarnet or cidofavir. Without pharmacological intervention, drug-resistant HSV-1 
disease can become life-threatening through visceral dissemination. Since resistance to 
foscarnet has also been detected, it is imperative that novel therapeutics are developed.  
 Targeting cellular factors is a promising strategy for developing therapeutics to 
treat drug-resistant HSV-1 disease for two reasons. First, inhibitors targeting a cellular 
factor will work through a different mechanism of action from acyclic guanosine 
analogues. Second, the chance of a resistant virus emerging is substantially mitigated. It 
is well established that HSV-1 infection activates the host DNA damage response 
through the ATM pathway. Small molecule inhibitors targeting the DDR have been 
vigorously pursued as chemosensitizing agents for cancer treatment (378).  
KU-55933 was the first specific ATM inhibitor developed and inhibits ATM kinase activity 
in vitro with an IC50 of 12.9 nM (379). A major downstream target of ATM is Checkpoint 
Kinase 2 (Chk2), which phosphorylates a host of factors to further transduce the DDR. A 
common small molecule inhibitor that specifically targets Chk2 is Chk2 Inhibitor II (also 
known as BML227) which has an in vitro IC50 of 15 nM (380). Due to poor 
pharmacokinetic properties, these compounds have not been tested in clinical studies, 
but they are highly effective and commonly used in tissue culture models.  
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 Our lab previously discovered that both KU-55933 and Chk2 Inhibitor II are 
effective at inhibiting HSV-1 in models of herpes simplex keratitis (341, 342). Since 
recurrent HSV-1 infections most commonly occur as HSL, testing the efficacy of these 
inhibitors in oral mucosal models was warranted. To successfully elucidate virus-host 
interactions and identify ways to pharmacologically circumvent them, a physiologically 
relevant tissue culture cell line had to be identified. Many widely used cell lines are 
immortalized by either E6/E7 or SV40, but these methods of immortalization drastically 
alter the DDR (381). Therefore, our desired cell line had to be derived from a healthy, 
cancer-free human and immortalized with human telomerase. The cell line OKF6-TERT-2 
(referred to as OKF6) met these criteria, and was obtained from James Rheinwald at the 
Cell Culture Core of the Harvard Skin Disease Research Center in Boston, MA. OKF6 cells 
are a normal human primary oral keratinocyte cell line that was isolated from the floor-
of-mouth mucosa of a 57 year old healthy male and immortalized with ectopic 
expression of human telomerase (382). 
 In this chapter we characterize the HSV-1 induced DDR in OKF6 cells, and study 
the efficacy of KU-55933 and Chk2 Inhibitor II in this cellular setting. We also test the 
efficacy of KU-55933 and Chk2 Inhibitor II combined with acyclovir and on acyclovir-
resistant HSV-1 infection. We conclude this chapter with an evaluation of these 
inhibitors on a mouse model of HSL. 
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Results 
Establishment of an In Vitro Model for Oral Mucosal HSV-1 Infection  
 HSV-1 infection of a monolayer of cells follows a Poisson distribution, and the 
number of cells infected at a given multiplicity of infection (MOI) can be estimated. 
Applying this concept, OKF6 cells were infected with HSV-1 over a range of MOI, and 
infected cells were quantified by indirect immunofluorescence of the viral factor ICP8 
(Figure 3.1A). The percentage of infected OKF6 cells matched the anticipated numbers 
very closely (Figure 3.1B). This established the OKF6 cell line as an acceptable model for 
HSV-1 infection, and validated that MOI can be accurately calculated for infection of 
OKF6 cells.  
 
HSV-1 Infection Activates the ATM branch of the DDR in Oral Mucosal Cells  
 Next, we determined whether HSV-1 infection of oral mucosal cells activates the 
DNA damage response. Protein lysates were collected over a timecourse of HSV-1 
infection and probed with phospho-specific antibodies for targets of ATM. 
Autophosphorylation of ATM on serine 1981 (pATM-S1981) causes a conformational 
shift that activates the catalytic activity of ATM and is a marker representing ATM 
activation (292). Chk2 and Kap1 are both well-established ATM targets and get 
phosphorylated on threonine 68 (pChk2-T68) and serine 824 (pKap1-S824), respectively 
(319, 383). In response to HSV-1 infection, ATM targets were phosphorylated in 
different patterns. Low levels of pATM-S1981 and pKap1-S824 were detected as early as 
0.5 hpi, followed by robust activation by 4 hpi (Figure 3.2).  ATM and Kap1 
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phosphorylation both increased up to 4 hours and remained at this level for all 
remaining time points analyzed. In contrast, pChk2-T68 appeared robustly in the first 
0.5-1 hour post infection before disappearing completely by 4 hpi. The phosphorylation 
of threonine 68 can be removed by protein phosphatase 2A (PP2A) (384). To determine 
if PP2A was responsible for the loss of Chk2 phosphorylation during later stages of HSV-
1 infection, OKF6 were treated with a range of okadaic acid, a PP2A inhibitor (Figure 
3.3). Treatment with okadaic acid did not prevent the removal of this phosphorylation 
mark, indicating that a different cellular or viral phosphatase is responsible. It is 
important to note that Chk2 retains its catalytic activity as a kinase despite the removal 
of phosphorylation on threonine 68 (323, 385).   
Recruitment of DDR factors to RCs is a frequently observed characteristic of HSV-
1 infection. Indirect immunofluorescence (IF) conducted with antibodies against pATM-
S1981 and pKap1-S824 revealed that both ATM and Kap1 bearing these DDR-specific 
phosphorylations co-localize to HSV-1 RCs (Figure 3.4). These data demonstrate for the 
first time that Kap1 is phosphorylated and recruited to HSV-1 RCs. Our observations of 
ATM activation and phosphorylation of Chk2 on threonine 68 are consistent with 
previous observations in HeLa and corneal epithelial cells (338, 341). 
 
Small Molecule Inhibitors against ATM or Chk2 Suppress HSV-1 Infection 
 Replication of HSV-1 is severely hindered in cells lacking a functional ATM kinase, 
indicating that ATM activity is required for productive HSV-1 infection (338). This 
suggests that targeting ATM with a small molecule inhibitor could suppress HSV-1 
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infection. To test this hypothesis, we treated OKF6 cells with the ATM small molecule 
inhibitor, KU-55933, at a range of concentrations and measured the production of 
infectious HSV-1 particles by plaque assay. Treatment with KU-55933 caused a dose-
dependent reduction in the amount of infectious HSV-1 particles produced over 20 
hours. (Figure 3.5A). Another way to evaluate the efficacy of inhibiting ATM is by 
measuring the viral genome copies produced by quantitative real time PCR (qPCR).  
Treatment with KU-55933 caused a dose-dependent reduction in HSV-1 genome copies 
produced over 20 hours (Figure 3.5B). The toxicity of KU-55933 was assessed through a 
colony survival assay. Treatment of OKF6 cells with 10 µM KU-55933 for 20 hours 
caused an approximately 30% decrease in survival, however this effect was not 
significantly different from vehicle conditions (Figure 3.6).  
. A major way in which ATM carries out the plethora of downstream functions in 
the DDR is by activating additional kinases, such as Chk2. ATM phosphorylation of Chk2 
on threonine 68 induces dimerization and the formation of an active kinase domain. 
Since we detected pChk2-T68 in response to HSV-1 infection, we hypothesized that 
Chk2 has a required function in HSV-1 infection that can be targeted to suppress HSV-1 
infection. We treated HSV-1 infected OKF6 cells with Chk2 Inhibitor II and assessed the 
impact of Chk2 inhibition on HSV-1 replication. HSV-1 genome copy numbers were 
reduced in a dose-dependent manner in response to Chk2 Inhibitor II treatment, 
demonstrating that Chk2 activity was necessary for HSV-1 infection in oral mucosal cells 
(Figure 3.7). To further evaluate the effectiveness of ATM and Chk2 Inhibitor II on HSV-1 
infection, HSV-1 infected OKF6 cells were treated with KU-55933 (10 µM) or Chk2 
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Inhibitor II (10 µM), and the replication of HSV-1 was measured over a 20 hour time 
course of infection in comparison to acyclovir treatment (50 µg/ml). Measuring the 
amount of infectious HSV-1 particles produced (Figure 3.8A) and the number of HSV-1 
genome copies (Figure 3.8B) demonstrated that both KU-55933 and Chk2 Inhibitor II 
were highly effective at reducing HSV-1 replication throughout the duration of the 
experiment at a level comparable to acyclovir.  
 
ATM and Chk2 Inhibitors Suppress HSV-1 Infection in an Additive Manner with Acyclovir 
 The combination of two or more therapeutics is a strategy that can improve the 
overall efficacy of disease treatment while reducing the toxicity concerns that may be 
associated with a high dose of single agent. We assessed the potential for combining 
acyclovir with either KU-55933 or Chk2 Inhibitor II. Infected OKF6 cells were treated 
with concentrations of acyclovir or KU-55933 that alone produced a low level of HSV-1 
inhibition (Figure 3.9A; lanes 2 and 3). When OKF6 cells were treated with both 
inhibitors simultaneously, they had an additive effect in inhibiting HSV-1 replication 
(Figure 3.9A; lanes 4 and 5). The same experiment was performed with acyclovir and 
Chk2 inhibitor II, and the combination of the two compounds also produced an additive 
effect in inhibiting HSV-1 replication (Figure 3.9B). 
 
ATM and Chk2 Inhibitors Suppress Drug-Resistant HSV-1 Infection  
Since KU-55933 and Chk2 Inhibitor II target cellular factors, we hypothesized that 
they would inhibit replication of the acyclovir-resistant HSV-1 strain, dlspTK (386). The 
69 
 
efficacy of KU-55933 and Chk2 Inhibitor II treatment on dlspTK replication was tested in 
comparison to the KOS strain in OKF6 cells. A high concentration of acyclovir (50 µg/ml) 
reduced replication of KOS but was very limited in its ability to suppress dlspTK 
replication. In contrast, KU-55933 treatment significantly inhibited replication of both 
KOS and dlspTK (Figure 3.10A). Treatment with Chk2 Inhibitor II also reduced replication 
of the dlspTK strain (Figure 3.10B). These results demonstrate that acyclovir-resistant 
HSV-1 viruses are susceptible to inhibitors targeting the DDR response.  
 
Formulation of KU-55933 and Chk2 Inhibitor II for Topical Delivery 
To test the efficacy of KU-55933 and Chk2 inhibitor II in a more clinically relevant 
setting, we used a mouse model of herpes simplex labialis (387). In order to test the 
topical application of KU-55933 and Chk2 Inhibitor II, they needed to be prepared in a 
formulation where high concentrations can be achieved and could penetrate the outer 
layer of the mouse lip. DMSO is the common vehicle used for these compounds, but at 
high concentrations it can inhibit HSV-1 infection (388). An alternative solution 
consisting of 5% DMSO, 47.5% polyethylene glycol 300, and 47.5% water (referred to as 
PEG) was recommended by the company SelleckChem (Houston,TX). Stock 
concentrations of 2 mM were successfully achieved for each compound in PEG solution. 
Initial experiments were performed on OKF6 cells to ensure that each inhibitor retained 
its anti-HSV-1 efficacy in the PEG solution. Light phase images taken of HSV-1 infected 
OKF6 cells treated with KU-55933 or Chk2 Inhibitor II showed no difference in 
phenotype when the inhibitors were prepared in PEG solution versus DMSO (Figure 
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3.11A). Quantification of HSV-1 genome copy numbers revealed that both KU-55933 
and Chk2 Inhibitor II suppressed HSV-1 infection when they were prepared in PEG 
solution; there was no noticeable difference in efficacy when prepared in PEG compared 
to DMSO (Figure 3.11B). Furthermore, the PEG solution was visually absorbed very 
quickly (under 5 minutes) into the lip tissue of mice. In conclusion, high concentrations 
of KU-55933 and Chk2 Inhibitor II can be achieved in a PEG solution that retains the 
effectiveness of the compounds and is optimized for penetration into mouse skin. 
 
Inhibition of ATM or Chk2 Reduces Disease Severity in a Mouse Model of Herpes Simplex 
Labialis.  
The lower lips of BALB/c mice were infected with the McKrae strain of HSV-1. 
Treatments were applied topically to the site of infection starting at 4 hours post 
infection and were reapplied once daily for the next 5-6 days (Figure 3.12A). In this 
mouse HSL model, symptoms will arise over the course of 5 to 6 days that resemble 
human HSL. These symptoms were scored based on their physical appearance, and this 
was used to track the progression of disease and measure the efficacy of topical 
treatments (Figure 3.12B). Treatment with either KU-55933 or Chk2 Inhibitor II 
produced a statistically significant decrease in the progression of HSL lesions when 
compared to a vehicle control (Figure 3.13). Another characteristic of HSV-1 infection is 
weight loss; mice were weighed daily, and the groups treated with KU-55933 or Chk2 
Inhibitor II experienced less weight loss than the vehicle-treated control group during 
the course of infection (Figure 3.14). Histological analysis of lip tissues from uninfected 
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mice that were treated with KU-55933 or Chk2 Inhibitor II under the same treatment 
regimen showed no drug-induced cytotoxic changes compared to the normal mucosal 
epithelium (Figure 3.15). These results establish that inhibitors against ATM or Chk2 are 
efficacious at reducing symptoms of HSV-1 infection in an animal model of herpes 
simplex labialis. 
 
Conclusions 
 In these experiments, we have successfully demonstrated that HSV-1 induces the 
DNA damage response in oral mucosal epithelial cells by activating ATM and Chk2. The 
immortalized cell line, OKF6, represents a physiologically relevant cell line for the in vitro 
study of HSV-1 infection. Targeting ATM or Chk2 with the small molecule inhibitors KU-
55933 and Chk2 Inhibitor II, respectively, significantly suppresses HSV-1 infection. This 
was demonstrated in vitro by measuring the production of infectious particle and 
genome copy numbers over a time course of infection.  
 The utility of targeting the DDR was expanded by a series of additional 
experiments. First, both KU-55933 and Chk2 Inhibitor II suppressed HSV-1 infection in an 
additive manner when combined with acyclovir. Next, both of these inhibitors very 
effectively suppressed acyclovir-resistant HSV-1. Finally, the topical administration of 
either inhibitor was efficacious in a mouse model of HSL. Overall, we have established 
that targeting the DDR has great potential for treating oral mucosal HSV-1 disease. 
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Figure 3.1: HSV-1 Infection in OKF6 Cells Follows a Poisson Distribution. (A) OKF6 cells 
were infected with HSV-1 at a range of multiplicities of infections (MOI) and fixed at 4 
hpi. Indirect immunofluorescence was performed with an antibody against ICP8 (red) 
and a Hoescht counterstain. (B) The expected infectivity values were calculated based 
on Poisson distribution and the values on the right was derived experimentally by 
calculating the number of ICP8 positive cells divided by the number of total cells. n = 3 
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Figure 3.2: HSV-1 Infection in Oral Mucosal Cells Activates ATM. OKF6 cells were 
infected with HSV-1 at a MOI of 5 and protein lysates were collected at the indicated 
times. Western Blots were performed using antibodies against viral factors (ICP0, ICP8, 
gB, and gC) and factors in the DDR (ATM, Chk2, Kap1). Phospho-specific antibodies for 
ATM targets (pATM-S1981, pChk2-T68, and pKap1-S824) were used to assess the 
activity of the DDR. Nucleolin was used as a loading control. 
  
 
74 
 
 
 
Figure 3.3: PP2A does not Dephosphorylate pChk2-T68 During HSV-1 Infection. OKF6 
cells were infected at a MOI of 5 in the presence of okadaic acid at the indicated 
concentration. Protein lysates were collected at 2.5 hpi or 8 hpi and Western Blot was 
performed and probed with antibodies against ICP0, gC, pChk2-T68, and total Chk2. 
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Figure 3.4: Phosphorylated ATM and Kap1 Co-localize to HSV-1 Replication 
Compartments in Oral Mucosal Cells. OKF6 cells were infected at a MOI of 5, fixed at 4 
hpi, and processed for IF by probing for ICP8 (green) and pATM-S1981 (red) or ICP8 (red) 
and pKap1-S824 (green). Hoechst was used as a nuclear counterstain. 
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Figure 3.5: Inhibition of ATM Reduces HSV-1 Viral Yields and Genome Copy Numbers 
in a Dose-Dependent Manner. (A and B) OKF6 cells were infected with HSV-1 at a MOI 
of 0.1 and treated with a range of KU-55933 concentrations. (A) Media was collected 
from infected cells at 20 hpi and viral yields were calculated by conducting plaque 
assays. n = 3 (B) Total DNA lysates were collected at 20 hpi and HSV-1 genome levels 
were quantified by qPCR. n = 3. Data are means ± SEM. *Statistically significant. 
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Figure 3.6: KU-55933 is not Cytotoxic on OKF6 Cells. Survival of OKF6 in response to a 
20 hour treatment with KU-55933 (10 µM) was measured by colony survival. n = 3. Data 
are means ± SEM. 
 
78 
 
 
 
Figure 3.7: Inhibition of Chk2 Reduces HSV-1 Genome Copy Numbers in a Dose-
Dependent Manner. OKF6 cells were infected with HSV-1 at a MOI of 0.1 and treated 
with a range of Chk2 Inhibitor II concentrations. Total DNA lysates were collected at 20 
hpi, and HSV-1 genome levels were quantified by qPCR. n = 2. Data are means ± SEM. 
*Statistically significant. 
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Figure 3.8: Inhibition of ATM or Chk2 Suppresses HSV-1 Throughout the Lytic Lifecycle. 
OKF6 cells were infected with an MOI of 0.1 and treated with vehicle (DMSO), 10 µM 
KU-55933, 10 µM Chk2 Inhibitor II, or 50 µg/ml Acyclovir. (A) Media was collected from 
infected cells and viral yields were calculated by conducting plaque assays. n = 2 (B) 
Total DNA lysates were collected at 20 hpi and HSV-1 genome levels were quantified by 
qPCR. n = 2. Data are means ± SEM. *Statistically significant. 
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Figure 3.9: Acyclovir Combined with KU-55933 or Chk2 Inhibitor II Suppresses HSV-1 
Infection in an Additive Manner. (A and B) OKF6 were infected with KOS at a MOI of 
0.1. Total DNA lysates were collected at 20 hpi and HSV-1 genomes were measured by 
qPCR. (A) OKF6 cells were treated with acyclovir (0.5 µg/ml) or KU-55933 (1.00 µM and 
2.00 µM) individually (black and grey bars) or in combination (red). n = 3. (B) OKF6 cells 
were treated with acyclovir (0.5 µg/ml) or Chk2 Inhibitor II (2.25 µM and 4.00 µM) 
individually (black and grey bars) or in combination (red bars). n = 3. Data are means ± 
SEM. 
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Figure 3.10: Inhibition of ATM or Chk2 Suppresses Replication of Acyclovir-Resistant 
HSV-1. (A and B) OKF6 cells were infected with KOS or dlspTK strains of HSV-1 at a MOI 
0.1 in the presence of acyclovir (50 µg/ml), (A) KU-55933 (10 µM), or (B) Chk2 Inhibitor II 
(10 µM). Total DNA lysates were collected at 20 hpi, and HSV-1 genome levels were 
measured by qPCR. n = 3. Data are means ± SEM. *Statistically significant. 
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Figure 3.11: Optimization of Topical Formulation. (A and B) OKF6 cells were infected 
with HSV-1 at a MOI of 0.1. Cells were treated with KU-55933 (10 µM) or Chk2 Inhibitor 
II (10 µM) prepared in DMSO or PEG solution. (A) Light phase contrast images of OKF6 
cells were taken at 20 hpi. (B) Total DNA lysates were collected at 20 hpi and HSV-1 
genome levels was measured by qPCR. n = 2. 
 
83 
 
 
 
Figure 3.12: Experimental Outline for In Vivo HSL Mouse Model of Infection. (A) 
Experimental outline: BALB/c mice were infected on the lower lip with 2.0 x 105 pfu of 
HSV-1 (McKrae). The site of infection was treated topically every 4 hours for the first 12 
hours after infection, followed by treatments every 8 hours until completion of the 
experiment. (B) Lesions were scored every 24 hours based on the appearance of 
symptoms. A description for how lesions were scored in included in this table. 
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Figure 3.13: Inhibition of ATM or Chk2 Reduces HSV-1 Symptoms in an In Vivo Model 
of Herpes Simplex Labialis. (A) Experimental outline: BALB/c mice were infected on the 
lower lip with 2.0 x 105 pfu of HSV-1 (McKrae). The site of infection was treated topically 
every 4 hours for the first 12 hours after infection, and additional treatments were 
applied every 8 hours until the completion of the experiment. (B) Lesions were scored 
every 24 hours based on the appearance of symptoms. (C) BALB/c mice were infected 
with HSV-1 and treated with vehicle (PEG), 400 µM KU-55933, or 400 µM Chk2 Inhibitor 
II. Lesions were scored every 24 hours and plotted. n = 8.  Data are means ± SEM. 
*Statistically significant. 
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Figure 3.14: Inhibition of ATM or Chk2 Prevents Weight Loss in Mice Infected with 
HSV-1. Mice from the experiment in Figure 3.13 were weighed once every 24 hours. n = 
8.  Data are means ± SEM.  
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Figure 3.15: Topical Administration of KU-55933 or Chk2 Inhibitor II does not 
Significantly Alter Histological Appearance of the Oral Mucosal Epithelium of Mice 
Lips. H&E stain of lip section taken from uninfected BALB/c mice that were treated with 
PEG solution, KU-55933 (400µM), or Chk2 Inhibitor II (400µM) for 6 days. The same 
treatment procedure outlined in Figure 3.12A was used.  
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Chapter 4: Circularization of the HSV-1 Genome Requires ATM Signaling 
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Introduction 
 Productive HSV-1 infection requires optimization of the cellular environment by 
both suppressing and activating cellular factors and pathways. Having demonstrated 
that inhibition of either ATM or Chk2 greatly reduces HSV-1 infection, our next goal was 
to elucidate the function of ATM and Chk2 signaling in HSV-1 infection. 
 The mammalian DDR is strongly linked to HSV-1 genome replication as numerous 
repair factors have been observed at HSV-1 RCs through indirect immunofluorescence 
(336, 338, 341, 343, 373, 376, 377). Since replication compartments overlap with 
cellular sites of DNA replication, it cannot be ascertained if repair factors associate 
specifically with viral DNA. However, mass spectrometry revealed the interaction of 
many repair factors with the viral ssDNA binding protein, ICP8. Also, the maturation of 
RCs was delayed in cells lacking Mre11 activity (338). The reason for DDR involvement at 
sites of active DNA replication is unclear. The viral genome contains nicks and gaps that 
might produce DSB during replication and require repair through homologous 
recombination (389-392). Also, the HSV-1 genome undergoes a high level of 
recombination at the onset of DNA replication, which may require the mammalian DDR 
(235). In addition to having a direct role during active DNA synthesis, there are many 
events leading up to viral DNA replication that may necessitate involvement of the DDR.    
 Replication of the HSV-1 genome requires seven essential viral factors. In order 
for these viral proteins to be expressed, the intrinsic antiviral response must be 
counteracted. When the HSV-1 genome enters the nucleus, it is initially coated with the 
heterochromatin factor CHD3 and bears repressive H3K9me2, H3K9me3 and H3K27me3 
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methylation histone marks (205, 266, 393). Additionally, the heterochromatin factor 
HP1 is associated with ND10 structures and can associate with quiescent HSV-1 (394). 
An inability to overcome this heterochromatin barrier impedes the production of viral 
genes necessary for DNA replication. The DDR response is equipped with ways to 
modulate the chromatin landscape. Importantly, ATM phosphorylation of Kap1 on 
serine 824 causes heterochromatin decondensation (319). Since Kap1 binds directly to 
CHD3, associates with HP1 and H3K9Kme2/3, and gets phosphorylated by ATM in 
response to HSV-1 infection, the virus may be hijacking the ATM signaling pathway to 
alleviate heterochromatin through Kap1 phosphorylation (317-319).  
 Replication of HSV-1 DNA initiates through a theta mechanism before converting 
to a rolling circle mechanism (235). This replication strategy requires a circular DNA 
template. Since the HSV-1 genome is delivered into the nucleus as a linear structure, the 
terminal ends must be joined together through a process commonly referred to as 
circularization (186, 395, 396). Very little is known about the mechanism responsible for 
circularization, but it can occur independently of de novo viral synthesis (395). Based on 
this observation, it has been postulated that circularization occurs through the 
involvement of cellular factors and/or the tegument. The terminal ends of the HSV-1 are 
part of the repetitive a sequence in the HSV-1 genome, which has led to hypotheses 
that circularization can occur through NHEJ or HR (186, 374, 397). Since ATM signaling is 
upstream of both HR and NHEJ, it is feasible that HSV-1 activates and utilizes ATM 
signaling for circularization. 
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 In this chapter we investigated the potential role of ATM signaling in HSV-1 
chromatin modulation. Studies were designed to determine if Kap1 was an antiviral 
factor that HSV-1 subverted through ATM activation. Further experimentation with KU-
55933 and Chk2 Inhibitor II identified how ATM and Chk2 signaling regulates viral gene 
expression and revealed when ATM and Chk2 are required during the lytic life cycle. We 
conclude with an investigation on the role of ATM and Chk2 activities on HSV-1 genome 
circularization. 
 
Results 
ATM Phosphorylation of Kap1 does not have an Effect on HSV-1 Replication 
 Expression of immediate early and early genes is a requirement for HSV-1 DNA 
replication. To accomplish this, HSV-1 must overcome the host’s intrinsic attempts at 
suppressing gene expression by packaging the viral genome into heterochromatin. Some 
of the heterochromatin marks that have been shown to interact with the genome are 
HP1 and CHD3 (393). Interestingly, these factors are frequently associated with Kap1. As 
we identified in Chapter 3, Kap1 gets phosphorylated on its ATM target site, serine 824, 
in response to HSV-1 infection. This post-translational modification has a significant 
impact on decondensing the heterochromatin structure into a more accessible 
euchromatin-like structure (explained in greater detail in Chapter 2). Based on these 
observation we envisioned a scenario where Kap1 functions in the intrinsic antiviral 
response to suppress HSV-1 by packaging the incoming genome into heterochromatin. 
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Under such conditions, HSV-1 could thwart the host defense by activating ATM and 
causing phosphorylation of Kap1 on serine 824. 
 To test this hypothesis, we reasoned that knock down of Kap1 would have the 
same effect at reversing heterochromatin as phosphorylation of serine 824. Kap1 was 
knocked down by shRNA and HSV-1 infected OKF6 cells were treated with KU-55933. In 
this experiment, OKF6 cells were infected at a MOI of 0.1 and protein lysates were 
collected at 20 hpi. Under these experimental conditions, ~15 % of cells are initially 
infected (Figure 3.1) followed by multiple rounds of infection that result in complete 
infection of the monolayer by 20 hours. The expression of HSV-1 factors ICP0 and gC 
were severely reduced by KU-55933, indicating that KU-55933 suppressed HSV-1 
replication in the initial ~15% of infected cells and prevented further infection of the 
monolayer (Figure 4.1). ICP0 and gC levels were similarly low when Kap1 was knock 
downed, demonstrating that reducing Kap1 levels did not rescue the effects of KU-
55933. This observation was further substantiated through the use of Kap1 expression 
constructs with mutations at the serine 824 phosphorylation site. Stable OKF6 cells were 
created expressing ectopic wild type (wt), phospho-dead (S824A), or phospho-mimetic 
(S824D) Kap1 constructs that are resistant to shRNA. Endogenous Kap1 was knocked 
down through shRNA and OKF6 cells were infected with HSV-1 in the presence of 
vehicle (DMSO) or KU-55933. Expression of Kap1 was verified by Western Blot (Figure 
4.2A). Measurement of viral genome copy numbers by qPCR revealed that manipulation 
of the ATM phosphorylation site of Kap1 had no significant effect on the replication of 
HSV-1 under vehicle or KU-55933 treatment conditions (Figure 4.2B). Based on these 
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results, we can conclude that phosphorylation of Kap1 by ATM is not required for HSV-1 
replication 
 
ATM and Chk2 Activities are Required for Expression of True Late HSV-1 Factors 
 It still remained possible that ATM was needed to alter the HSV-1 chromatin 
landscape in a manner independent of Kap1. To test this hypothesis, we took a more 
holistic approach and analyzed the expression of HSV-1 factors representative of 
different viral genes in the presence of KU-55933. To our surprise, we found that the 
expression of ICP0 (immediate early; IE), ICP8 (early; E), and gB (leaky late) were not 
affected by ATM inhibition (Figure 4.3). This disproved our hypothesis that ATM 
signaling was necessary for regulating the global chromatin structure of the HSV-1 
genome. However, we observed that gC (true late) was severely suppressed by ATM 
inhibition. ATM inhibition had a similar impact at the transcript level; ICP0 (IE) and HSV-
1 Thymidine Kinase (E) were transcribed in the presence of KU-55933, but gC (true late) 
was significantly reduced (Figure 4.4). There was also a large reduction in gC expression 
in OKF6 cells treated with Chk2 Inhibitor II (Figure 4.5). That inhibition of ATM or Chk2 
only caused a reduction in a true late HSV-1 gene suggests that ATM and Chk2 are 
required for HSV-1 DNA replication.   
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ATM and Chk2 Activities have an Essential role During the First 3 Hours of HSV-1 
Infection 
To gain insight into how the DDR mechanistically contributes to HSV-1 DNA 
replication, the precise time at which ATM and Chk2 activity are required was 
determined. Experimentally, a synchronized infection was established by inoculating 
OKF6 cells with HSV-1 for 1 hour at 4°C before initiating infection by transitioning the 
cells to 37°C (Figure 4.6). KU-55933 or Chk2 Inhibitor II were added at different times 
before or during HSV-1 infection, and the expression of HSV-1 factors was analyzed 8 
hours post infection. There was no noticeable difference in ICP0 or ICP8 expression 
levels compared to wild type infection regardless of the time at which KU-55933 or Chk2 
inhibitor II were added (Figure 4.7). Expression of gC was completely inhibited when 
either inhibitor was added to cells before infection or within the first hour of infection 
and was partially inhibited when either inhibitor was added between 2 to 3 hours after 
the initial infection. The efficacy of either inhibitor was completely lost when added at 4 
hpi, as gC was expressed at the same level as seen in the absence of drug. These data 
indicate that ATM and Chk2 signaling are required during the initial 3-4 hours, with a 
significant impact in the first hour of infection. 
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Circularization of the HSV-1 Genome Requires ATM Signaling 
Circularization of the HSV-1 genome also occurs during the first 3 to 4 hours of 
HSV-1 infection, and is complete by 4 hpi. Additionally, circularization is a prerequisite 
for DNA replication and occurs when de novo synthesis of viral factors is blocked (186, 
374, 395, 397, 398). Since the joining of double stranded DNA (dsDNA) ends is a major 
function of the DNA damage response, we hypothesized that ATM is required for 
circularization of the HSV-1 genome. We employed a Southern Blot approach to 
measure the conformation of the terminal HSV-1 DNA ends (explained in detail, Figure 
4.8).   
The linear conformation of the HSV-1 genome was measured when OKF6 cells 
were infected in the presence of KU-55933 or Chk2 inhibitor II. Phosphonoacetic acid 
(PAA) was added under all conditions to prevent the production of newly synthesized 
HSV-1 genomes. DNA collected from virions was used as a control for the linear readout 
and produced the expected 3.4kb and 6kb bands (Figure 4.9). Wild type infection of 
OKF6 cells was carried out in the presence of a vehicle control (DMSO) and the 3.4 kb 
band was significantly reduced compared to the linear virion; indicating that the 
genome circularized. Inhibition of ATM resulted in a more intense 3.4 kb band 
compared to control (DMSO) but was not as strong as the band observed in the virion 
sample. Inhibition of Chk2 produce a pattern very similar to control (DMSO).  
The amount of HSV-1 that remained linear was quantified across 3 independent 
experiments by calculating the intensity of the 3.4kb band relative to the 6kb band and 
normalizing that value to the virion control (Figure 4.10). Under wild type conditions, 
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the proportion of linear genomes was 25.48% compared to the virion control, indicating 
that the majority of genomes formed an endless, circular structure. The residual linear 
genomes that are detected under wild type conditions likely result from linear genomes 
that are retained in particles, as previously reported (395). Treatment with KU-55933 
increased the proportion of linear genomes to 59.66% compared to the virion control, 
indicating that circularization was impeded by ATM inhibition. Treatment with Chk2 
inhibitor II resulted in 31.18% of genomes being in a linear state, which is not 
significantly different from wild type infection (DMSO) and demonstrates that 
circularization does not require Chk2 signaling. These results reveal that optimal 
circularization requires the ATM-dependent DDR and is independent of Chk2 signaling, 
which is still required for replication but not for circularization 
 
Conclusions 
 In summary, we have greatly expanded our knowledge on how HSV-1 
utilizes the host DDR. Inhibition of ATM activity did not preclude the expression of IE, E, 
or leaky late HSV-1 genes, which indicates that the viral genome achieves a permissible 
state for transcription independently of the DDR. Additionally, ATM phosphorylation of 
Kap1 on serine 824 did not have a functional role in HSV-1 infection. Therefore we can 
conclude that Kap1 is not a component of the intrinsic antiviral response, and that 
obtaining a permissible chromatin state for the expression of IE, E, or leaky late genes 
does not require ATM signaling. 
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We found that ATM and Chk2 signaling were required for the expression of the 
true late gene, gC, which implicates a role for ATM and Chk2 signaling in HSV-1 genome 
replication. ATM and Chk2 activity are both required during the first 3 to 4 hours of HSV-
1 infection, with a greater impact in the first hour. This timeframe coincides with HSV-1 
genome circularization. Inhibition of ATM signaling caused nearly 60% of the viral 
genomes to be retained in a linear conformation. This is the first evidence 
demonstrating a role for ATM signaling in HSV-1 genome circularization. Circularization 
was not impacted by Chk2 inhibition, indicating that ATM is required for circularization 
in a Chk2-independent manner. Since Chk2 signaling is still required for HSV-1 DNA 
replication, this demonstrates that multiple functions downstream of ATM activation 
are required for HSV-1 replication.  
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Figure 4.1: Kap1 Knockdown does not Rescue KU-55933 Suppression of HSV-1. OKF6 
cells were transduced with non-targeting (NT) shRNA or Kap1 shRNA before being 
infected with HSV-1 at a MOI of 0.1 in the presence of vehicle (DMSO) or KU-55933. 
Protein lysates were collected at 20 hpi and blotted for ICPO, gC, Kap1, pKap1-S824. 
Nucleolin was used as a loading control. 
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Figure 4.2: Phosphorylation of Kap1 on Serine 824 is not Required for HSV-1 Infection. 
(A) Stable OKF6 cells were selected for that expressed Kap1 constructs: empty backbone 
(LXSN), wild type (Kap1 wt), phospho-dead (Kap1 S824D), phospho mimetic (S824D). 
Each cell line was then transduced with Kap1 shRNA to knock down the expression of 
endogenous Kap1; the Kap1 expression constructs were resistant to the shRNA target 
sequence. (A) Protein lysates were collected and probed for HA, Kap1, and Nucleolin to 
assess the exogenous expression of Kap1 constructs. (B) OKF6 cells from (A) were 
infected with HSV-1 at a MOI 0.1 and treated with vehicle (DMSO) or KU-55933. Total 
DNA lysates were collected at 8 and 20 hpi, and HSV-1 genome levels were quantified by 
qPCR. 
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Figure 4.3: Inhibition of ATM Suppresses Expression of True Late HSV-1 Genes. OKF6 
cells were infected with HSV-1 at an MOI of 5 in the presence of vehicle (DMSO) or KU-
55933 (10 µM). Protein lysates were collected at the indicated times and blotted for 
HSV-1 proteins representing the different gene classes: ICPO (IE), ICP8 (E), gB (Leaky 
Late), and gC (True Late). ATM targets Chk2 and Kap1 were also probed to verify that 
KU-55933 inhibited ATM. Nucleolin was used as a loading control.  
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Figure 4.4: Inhibition of KU-55933 or Chk2 Suppresses Transcription of True Late HSV-1 
Genes. OKF6 cells were infected with HSV-1 at an MOI of 0.1 in the presence of vehicle 
(DMSO), KU-55933 (10 µM), Chk2 Inhibitor II (10 µM), or acyclovir (50 µg/ml). Total RNA 
lysates were collected at the indicated time points and transcript levels were quantified 
by qPCR for HSV-1 genes representing the different gene classes: (A) ICP0 (IE), (B) HSV-1 
Thymidine Kinase (E), and (C) gC (True Late). n = 2. Data are means ± SEM. *Statistically 
significant. 
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Figure 4.5: Inhibition of Chk2 Suppresses Expression of True Late HSV-1 Genes. OKF6 
cells were infected with HSV-1 at an MOI of 5 in the presence of vehicle (DMSO) or Chk2 
Inhibitor II (10 µM). Protein lysates were collected at the indicated times and blotted for 
HSV-1 proteins representing the different gene classes: ICPO (IE), ICP8 (E), gB (Leaky 
Late), and gC (True Late). Nucleolin was used as a loading control. 
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Figure 4.6: Experimental Outline: Impact of KU-55933 and Chk2 Inhibitor II 
Administration Timing. Experimental outline: OKF6 cells were inoculated with HSV-1 at 
a MOI of 5 at 4 °C (-1 hpi) for 1 hr. Inoculation at 4 °C allows HSV-1 to bind cells but 
prevents their entry. When cells are shifted to 37 °C, HSV-1 enters the cell at the same 
time; resulting in a synchronized infection. OKF6 cells were treated with KU-55933 (10 
µM) or Chk2 Inhibitor II (10 µM) prior to HSV-1 inoculation (-2 hpi), at the time of 
inoculation (-1 hpi) or at different times after inoculation (0 to 4 hpi). Protein lysates 
were collected at 8 hpi. 
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Figure 4.7: ATM and Chk2 Activity are Required in the First 3 to 4 Hours Post Infection. 
Protein lysates collected from OKF6 infected under the experimental outline explained 
in Figure 4.6 and were blotted for HSV-1 proteins representing the different gene 
classes: ICPO (IE), ICP8 (E), gB (Leaky Late), and gC (True Late). M = Mock, HSV = treated 
with vehicle (DMSO).  * -1hpi = Inhibitor was added during inoculation step.  Nucleolin 
was used as a loading control.  
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Figure 4.8: Experimental Outline: Measurement of HSV-1 Genome Circularization by 
Southern Blot. Total DNA lysates were collected from HSV-1 infected OKF6 cells. DNA 
was digested with BamH1 (relevant sites indicated by blue lines). Biotinylated probes 
(black line) that recognize the 3’- region of ICP4 downstream of the BamH1 cut site were 
synthesized. The probes recognize both the terminal and internal copies of the ICP4 
gene. If the genome is linear, the terminal probes will detect a 3.4 kb fragment of DNA 
(red). If the genome is circular, the terminal probes will detect a 6 kb fragment of DNA 
(green). Under either situation, the internal ICP4 probes will always recognize a 6 kb 
fragment. In summary: A linear HSV-1 genome will produce a 3.4 kb and 6 kb band. A 
circular genome will only produce a 6 kb band. 
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Figure 4.9: ATM Inhibition Limits Circularization of the HSV-1 Genome. OKF6 cells were 
infected with HSV-1 at a MOI of 1 in the presence of vehicle (DMSO), KU-55933 (10 µM), 
or Chk2 Inhibitor II (10 µM). Under all conditions, PAA (400 µg/ml) was included to 
prevent the production of progeny HSV-1 genomes. DNA was collected at 3 hpi, 
isolated, digested with BamH1, run on southern blot and probed with biotinylated 
probes specific for the 3’-portion of the ICP4 gene. Data shown are representative of 3 
individual experiments. 
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Figure 4.10: ATM Inhibition Causes a Significant Increase in the Amount of Detectable 
Linear HSV-1 genomes. The amount of linear HSV-1 genomes was quantified by dividing 
the densitometry ratio of the 3.4kb band by the 6kb band and normalizing to the virion 
ratio. n = 3. Data are means ± SEM. *Statistically significant. 
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Chapter 5: ICP4 is Required for ATM Activation in HSV-1 Infection 
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Introduction 
 The DDR is composed of a vast network of factors that are regulated by three 
apical kinases, ATM, ATR, and DNA-PKcs (276). These kinases targets a large number of 
substrates to modulate numerous physiological processes in the cell. HSV-1 has evolved 
ways to activate ATM while silencing ATR activity and degrading DNA-PKcs (217, 337, 
338, 340). These observations reveal a preference for the ATM pathway. We 
demonstrated in Chapter 3 and 4 that ATM signaling is required for HSV-1 replication in 
part through its function in circularizing the HSV-1 genome. 
 The manner in which ATM is activated by HSV-1 is not known, but a couple 
different hypotheses have been proposed. The viral genome delivered into cells 
contains nicks and gaps of missing nucleotides (389-392). It has been hypothesized that 
these genomic defects could be directly sensed as damage or lead to DSB during DNA 
replication, which would cause ATM activation (237). Another possible source of ATM 
activation are the exposed terminal ends of the incoming linear viral genome, which 
may be sensed as DSBs by MRN and ATM. These possibilities were experimentally ruled 
out by previous members of our laboratory. In response to HSV-1 infection, DNA 
damage could not be detected by comet assay (Alekseev, et al., in preparation). This 
ruled out that the possibility that ATM was being activated from DNA damage. 
Activation of ATM also occurred when cells were transfected with a bacterial artificial 
chromosome encoding the HSV-1 genome (Alekseev, et al., in preparation). This 
demonstrated that the exposure of terminal DNA ends were not required for ATM 
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activation. Rather, de novo synthesis of the HSV-1 genetic material was sufficient for 
activating ATM. 
 Certain viral factors have also been implicated in having a role in the DDR. Having 
established in Chapter 4 that ATM function is essential in the first hours of HSV-1 
infection, tegument factors and/or IE factors are prime candidates for influencing ATM 
activation. ICP0 is a strong candidate because it is both an IE gene and tegument factor 
and already has established roles in regulating the DDR by degrading DNA-PKcs, RNF8, 
and RNF168. Studies investing ICP0 have produced conflicting results. A study by Li et al. 
demonstrated that expression of ICP0 alone can cause activation of ATM and Chk2 
(349). A later study by Lilley et al. showed by IF that ATM was activated at high MOIs 
independently of ICP0; however ICP0 was required at low MOIs (338). The function of 
ICP0 is largely influenced by both MOI and the cellular environment; for example an 
ICP0 null virus can replicate at high MOI (354).  Thus, it is difficult to make direct 
comparisons between these two findings. 
 ICP4 is another IE viral factor that is also present in the tegument. A major 
function of ICP4 is to regulate the transcription of E and L genes. ICP4 has a DNA binding 
domain that recognizes a consensus RTCGTCNNYNYSG (R is purine, Y is pyrimidine, S is C 
or G, N is any base), which is necessary for activating the transcription of E genes (399). 
ICP4 binding to DNA is enhanced through its ability to multimerize and bind along the 
entire HSV-1 genome in a sequence-independent manner (400). ATM can be activated 
independently of DSBs through chromatin perturbations or by direct recruitment to 
chromatin. It is possible that ICP4 can activate ATM by directly recruiting it to the HSV-1 
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genome or indirectly by causing global chromatin alterations. In support of a role for 
ICP4 in activating ATM is the finding that ICP4 is required for circularization (398). 
 In this chapter, we sought to determine the necessary events and/or viral factors 
that cause ATM activation during HSV-1 infection. Initially, we analyzed ATM activation 
in experimental settings where de novo synthesis of viral factors was inhibited. These 
experiments revealed that ATM is fully activated through de novo synthesis, but is 
activated at partial levels independent of de novo synthesis. Through the use of mutant 
viruses, we assessed the role of ICP0 and ICP4 in ATM activation.  
.  
 
 
 
 
 
 
 
 
 
*Note: The work in this chapter was initiated by a previous lab member, Oleg Alekseev. 
Figures 5.1 - 5.4 are experiments I independently performed that repeat his initial 
findings.  
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Results 
Full Activation of ATM Requires De Novo Synthesis of Viral Factor(s) 
 Previous work in our lab determined HSV-1 infection did not induce DNA damage 
and exposure of the terminal HSV-1 genome ends were not required for ATM activation 
(Alekseev et al., in preparation). We hypothesized that a viral factor(s) expressed from 
the viral genome is responsible for activating ATM. To assess this postulation, we 
conducted a series of experiments that analyzed ATM activation at 1 hour post 
infection. We chose a 1 hpi time point for our analysis because the functional role of 
ATM begins within the first hour (Figure 4.7). Phosphorylation of Chk2 was used as a 
readout for ATM activation because it is a highly sensitive marker that could be more 
easily detected by Western Blot than ATM itself or other ATM targets (Figure 3.2). First, 
we sought to verify that phosphorylation of Chk2 on threonine 68 was ATM-dependent 
under these conditions. Treatment of hTCEpi cells with KU-55933 completely prevented 
pChk2-T68, verifying our previous results (Figure 4.5), and demonstrating that it can be 
used as a dependable readout for evaluating ATM activity at 1 hpi (Figure 5.1). 
 Cycloheximide (CHX) is an inhibitor of protein synthesis that will prevent the 
translation of cellular and viral mRNAs. hTCEpi cells were infected with HSV-1 at an MOI 
of 3 or 10 in the absence or presence of CHX (5 µg/ml). To our surprise, Chk2 was 
phosphorylated in the presence of CHX, but at a level that was significantly lower than 
wild type infection (Figure 5.2). This interesting result demonstrated that while protein 
synthesis is required for full activation of ATM, a low level of ATM activation occurs 
independently of de novo synthesis. However, this result does not provide any 
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information as to whether a cellular or viral factor(s) is responsible for the full activation 
of ATM. UV treatment of HSV-1 virions causes the formation of pyrimidine dimers in the 
viral genome, preventing the expression of all viral genes. Infection of hTCEpi cells with 
UV-inactivated HSV-1 produced a low level of pChk2-T68 compared to wild type 
infection (Figure 5.3). This pattern of ATM activation was very similar to that seen after 
CHX treatment (Figure 5.2), and suggested that full activation of ATM requires the 
expression of HSV-1 genes. To unequivocally determine if full activation of ATM was a 
result of an expressed HSV-1 factor(s), UV-inactivated HSV-1 was combined with CHX 
treatment. The level of pChk2-T68 detected in the combination of UV-inactivated HSV-1 
and CHX was similar to the level detected in either condition alone (Figure 5.4), 
indicating that CHX treatment did not have any further impact when viral gene 
expression was abrogated. Thus, we can conclude that full activation of ATM requires de 
novo synthesis of a HSV-1 factor(s), and that there is a mechanism that causes low levels 
of ATM activation independently of de novo synthesis. 
 
Activation of ATM does not Require ICP0 
 The low level of ATM activation that occurs independently of de novo synthesis is 
very fascinating. Since HSV-1 is equipped with tegument factors that optimize the 
cellular environment without the need for the expression of additional viral factors, we 
hypothesized that a tegument factor could activate ATM.  The responsible factor would 
be capable of activating ATM in two stages: 1) tegument copies could activate ATM 
independently of de novo synthesis 2) de novo synthesis of this factor will cause further 
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activation of ATM. This proposed situation would explain the observed partial ATM 
activation independent of de novo synthesis, and full ATM activation under conditions 
where de novo synthesis occurs. 
 ICP0 is a tegument factor that reportedly manipulates the DDR. The reports on 
whether ICP0 has a role in ATM activation have been conflicting. One study found that 
expression of ICP0 alone could cause ATM activation (349); in contrast, another study 
found that ICP0 expression was not required for infections conducted with an MOI of 5 
(338). To address the discrepancy in the literature about ICP0’s role in ATM activation, 
we compared wild type HSV-1 (KOS) infection to the 7134 mutant strain that lacks 
functional copies of both ICP0 genes (ICP0Δ). The challenge of using mutant strains of 
virus is obtaining an accurate titer in a non-complementing cell line.  Since the absence 
of ICP0 could affect the expression of other viral genes, high titer stock of ICP0Δ virus 
was made and “tittered” by comparison to expression levels of IE genes from tittered 
KOS.  To determine the requirement for ICP0, hTCEpi cells were infected with a range of 
concentrations of ICP0Δ virus added directly to the inoculum and compared to KOS 
infection at MOI 3 and 10 (Figure 5.5). ICP4 expression was quantified for ICP0Δ and 
compared to the values of ICP4 from KOS at MOI 3 and 10. On the basis of this 
calculation, a “titer” of the ICP0 virus could be used to produce equivalent levels of ICP4 
expression relative to KOS at MOI 3 and 10. This enabled a direct comparison between 
KOS and ICP0Δ viruses. hTCEpi cells were infected with KOS or ICP0Δ in the absence or 
presence of CHX, and ATM activation was measured through pChk2-T68 (Figure 5.6). 
Infection with ICP0Δ produced a nearly identical pattern of pChk-T68 with or without 
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CHX. This result demonstrates that ICP0 is not necessary for full activation of ATM that 
occurs through de novo synthesis or the partial level of ATM activation that occurs 
independently of de novo synthesis.  
  
Activation of ATM Requires ICP4 
Another tegument factor that has an important role in regulating the viral 
genome is ICP4. To evaluate the role of ICP4 in ATM activation, experiments were 
conducted with the d120 HSV-1 strain that lacks both copies of the ICP4 gene (ICP4Δ). 
The same optimization approach was undertaken that was used for ICP0Δ virus: hTCEpi 
cells were infected with a range of ICP4Δ virus and an infectious “titer” of ICP4Δ 
equivalent to KOS at MOI 3 or 10 was determined by quantifying the ICP0 band (Figure 
5.7). When ICP4Δ was compared to KOS in the absence or presence of CHX, a noticeable 
difference in pChk2-T68 levels was noticed (Figure 5.8). Low levels of pChk2-T68 were 
still observed by ICP4Δ in the presence of CHX, but a higher level of pChk2-T68 was not 
observed under vehicle conditions. This demonstrates that ICP4 is required for the de 
novo activation of ATM.   
ICP4 has multiple roles in HSV-1 infection based on its different functional 
domains. We used HSV-1 strains with mutations in different domains of the ICP4 gene to 
dissect which function of ICP4 is required for ATM infection. The i13 strain has a two 
amino acid insertion in the DNA binding domain of ICP4, which removes the 
transactivating properties of ICP4 (401). The n208 strain has a truncation of the 3’ end of 
the ICP4 gene, which prohibits ICP4 from multimerizing; n208 remains effective at 
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expressing E genes but is limited at expressing L genes (402, 403). Both i13 and n208 
were optimized for infection in the same manner ICP4Δ was (Figure 5.7 and Figure 5.9). 
Equivalent infectious titers of KOS, ICP4Δ, i13, and n208 were compared for their effect 
on ATM activation in the absence or presence of CHX. For both i13 and n208, pChk2-T68 
was detected at high levels under vehicle treatment and lower levels under CHX 
treatment (Figure 5.10). This pattern of pChk2-T68 very closely resembles KOS, and 
neither mutant virus shows a reduction in overall ATM activation that is observed with 
ICP4Δ. This result indicates that neither the sequence specific DNA binding domain nor 
the C-terminal multimerization domain are individually essential for ATM activation. 
 
De Novo Activation of ATM Requires Synthesis of Early HSV-1 Genes 
 Since ICP4 is required for the de novo activation of ATM, we wanted to 
determine if ATM activation was the result of an early gene product upregulated by 
ICP4. To address this question, we utilized the same experimental setup that was 
originally performed to characterize the kinetic gene classes of HSV-1 (219). Two 
essential components of this approach are the inclusion of CHX, an inhibitor of mRNA 
translation, and Actinomycin D, a general transcription inhibitor. First, cells were 
infected in the presence of CHX, to prevent the protein synthesis of all viral genes but 
allow the production of IE mRNAs. At 2 hpi, the CHX was removed to allow the IE mRNA 
to be translated, followed by the expression of E genes. However, immediate treatment 
with Actinomycin D after CHX removal allows translation of IE mRNA into protein 
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products but no transcription of the E genes. Thus, a cellular environment is established 
where IE proteins are present but E proteins are not.  
OKF6 cells were infected using this method; CHX was added to cells 1 hour 
before infection and maintained for the first 2 hours of infection before being 
transitioned into either: media with CHX, drug-free media, or media with Actinomycin D 
(Figure 5.11). Under these conditions, Chk2 phosphorylation cannot be used as a proper 
readout because in uninfected cells treatment with CHX and Actinomycin D caused Chk2 
phosphorylation (Figure 5.11; lane 2). Kap1 had very low levels of phosphorylation in 
response to CHX and Actinomycin D treatment, so it was used a readout of ATM activity 
instead (Figure 5.11; lane 2). Maintenance of CHX for the duration of the experiment 
reduced levels of pKap1-S824 (Figure 5.11; lane 3). When CHX was removed and 
replaced with drug free media, the expression of ICP0 (IE), ICP4 (IE) and ICP8 (E) genes 
occurred, and very high levels of pKap1-S824 were detected (Figure 5.11; lane 4). When 
CHX was removed and replaced with Actinomycin D, ICP0 (IE) and ICP4 (IE) were highly 
expressed but ICP8 (E gene) was reduced (Figure 5.11; lane 5), indicating that the 
procedure successfully established a cellular environment where only IE genes were 
expressed. The level of pKap1-S824 after Actinomycin D addition was significantly lower 
than the level detected when CHX was replaced with vehicle (Figure 5.11; lane 5 vs lane 
4). Since ICP4 and ICP0 were both expressed at a very high level with Actinomycin 
added, it does not appear that either of these viral factors can directly activate ATM. 
This result supports a model where full levels of ATM activation are reached due to the 
expression of an ICP4-dependent early gene(s). 
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Conclusion 
 We have identified that HSV-1 activates ATM through two mechanisms: the first 
mechanism is independent of de novo synthesis, while the second mechanism requires 
de novo synthesis. This conclusion was reached by performing HSV-1 infection under 
different conditions that abrogated de novo viral gene expression. First, infection in the 
presence of CHX demonstrated that ATM activity was reduced to a low, but detectable 
level. Infection with UV-inactivated HSV-1 produced a similar result. The combination of 
UV-inactivated HSV-1 with CHX produced a low level of pChk2-T68 that was consistent 
with either treatment condition alone, indicating that the decrease in ATM activity was 
due to both treatments altering HSV-1 gene expression and not cellular factors.  
 We investigated the role of ICP0 and ICP4 in ATM activation. We discovered that 
ICP0Δ virus activated ATM in a manner consistent with KOS; ATM is activated at full 
levels through de novo synthesis of a viral factor(s) and at low levels when de novo 
synthesis is inhibited. Thus, we can conclude that ICP0 does not have an essential role in 
activation of ATM. Next, we assessed the role of ICP4 in ATM activation. In contrast to 
ICP0Δ, ICP4Δ virus failed to produce full levels of ATM activation, demonstrating that 
ICP4 is essential for activation of ATM through de novo synthesis. Interestingly, low 
levels of ATM activation were detected under both vehicle and CHX treatment, 
indicating that activation of ATM independent of de novo synthesis does not require 
ICP4. However, the possibility of ICP4 playing a functional role cannot be completely 
ruled out because the tegument of ICP4Δ virus contains functional ICP4 produced by the 
complementing cell line it was propagated from.   
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Infection with mutant strains lacking specific functions of ICP4 demonstrated 
that the sequence specific binding of ICP4 and the C-terminal multimerization domains 
of ICP4 are not required. The role of ICP4 in de novo-dependent activation of ATM was 
further evaluated by an experiment that separated the expression of IE from E genes. 
This experiment showed a striking activation of ATM that is dependent on E genes. All 
together, these results suggest that ATM activation caused through de novo synthesis 
requires expression of an early factor(s) in an ICP4-dependent manner.  
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Figure 5.1: Phosphorylation of Chk2 is Dependent on ATM Activity. hTCEpi cells were 
infected with HSV-1 at the indicated MOI in the presence or absence of 10 µm KU-
55933. Total protein lysates were collected at 1 hpi and probed for Chk2, and pChk2-
T68. Phosphorylation of Chk2 served as a readout for ATM activity. α-tubulin was used 
as a loading control.  
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Figure 5.2: De Novo Protein Synthesis is Required for Full Activation of ATM by HSV-1. 
hTCEpi cells were infected with HSV-1 at the indicated MOI in the presence or absence 
of 5 µg/ml cycloheximide (CHX). Total protein lysates were collected at 1 hpi and probed 
for ICP0, ICP4, Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a readout for 
ATM activity. 
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Figure 5.3: UV-Inactivation of HSV-1 Reduces but does not Eliminate Activation of 
ATM. Prior to infection, HSV-1 was treated with 200 mJ/cm2 ultraviolet light (UV). 
hTCEpi cells were infected with HSV-1 at the indicated MOI. Total protein lysates were 
collected at 1 hpi and probed for ICP0, ICP4, Chk2, and pChk2-T68. Phosphorylation of 
Chk2 served as a readout for ATM activity. α-tubulin was used as a loading control.  
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Figure 5.4: Full Activation of ATM Requires De Novo Synthesis of a Viral Factor(s). Prior 
to infection, HSV-1 was treated with 200 mJ/cm2 ultraviolet light (UV). hTCEpi cells were 
infected with HSV-1 at the indicated MOI in the presence or absence of 5 µg/ml 
cycloheximide (CHX). Total protein lysates were collected at 1 hpi and probed for ICP0, 
ICP4, Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a readout for ATM 
activity. α-tubulin was used as a loading control.  
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Figure 5.5: Optimization of the ICP0Δ Mutant HSV-1 Strains. Prior to infection, HSV-1 
was treated with 200 mJ/cm2 ultraviolet light (UV). hTCEpi cells were infected with wild 
type HSV-1 (KOS) at the indicated MOI or with HSV-1 lacking ICP0 (ICP0Δ) with 
increasing amounts of virus. Total protein lysates were collected at 1 hpi and probed for 
ICP0, ICP4, Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a readout for ATM 
activity. α-tubulin was used as a loading control. 
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Figure 5.6: ICP0 is not Required for ATM Activation. hTCEpi cells were infected with 
wild type HSV-1 (KOS) at the indicated MOI or with HSV-1 lacking ICP0 (ICP0Δ) at 
comparable infectious titers. Total protein lysates were collected at 1 hpi and probed for 
ICP0, ICP4, Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a readout for ATM 
activity. α-tubulin was used as a loading control. *Estimated MOI. 
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Figure 5.7: Optimization of the ICP4Δ and i13 Mutant HSV-1 Strains. hTCEpi cells were 
infected with wild type HSV-1 (KOS) at the indicated MOI or with mutant ICP4 mutant 
HSV-1 strains at increasing infectious titers. ICP4Δ has a deletion for both copies of the 
ICP4 gene and i13 features a mutation in the DNA binding domain of ICP4. Total protein 
lysates were collected at 1 hpi and probed for ICP0, ICP4, Chk2, and pChk2-T68. 
Phosphorylation of Chk2 served as a readout for ATM activity. α-tubulin was used as 
loading control. 
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Figure 5.8: Activation of ATM Through De Novo Synthesis Requires ICP4. hTCEpi cells 
were infected with wild type HSV-1 (KOS) at the indicated MOI or with HSV-1 lacking 
ICP4 (ICP4Δ) at comparable infectious titers. Total protein lysates were collected at 1 hpi 
and probed for ICP0, ICP4, Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a 
readout for ATM activity. α-tubulin was probed as a loading control. *Estimated MOI. 
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Figure 5.9: Optimization of the n208 Mutant HSV-1 Strain.  hTCEpi cells were infected 
with wild type HSV-1 (KOS) at the indicated MOI or with the n208 mutant HSV-1 strain 
at increasing amounts of virus. The n208 strain has a deletion in the 3’-terminal region 
of the ICP4 gene. Total protein lysates were collected at 1 hpi and probed for ICP0, ICP4, 
Chk2, and pChk2-T68. Phosphorylation of Chk2 served as a readout for ATM activity. α-
tubulin was used as a loading control. 
 
 
 
 
128 
 
 
 
Figure 5.10: The DNA-binding and Multimerization Domains of ICP4 are not Required 
for ATM Activation. hTCEpi cells were infected with wild type HSV-1 (KOS) at the 
indicated MOI or with mutant ICP4 viruses at comparable infectious titers. Total protein 
lysates were collected at 1 hpi and probed for ICP0, ICP4, Chk2, and pChk2-T68. 
Phosphorylation of Chk2 served as a readout for ATM activity. α-tubulin was used as a 
loading control. 
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Figure 5.11: De Novo Activation of ATM Requires Expression of the Early HSV-1 
Gene(s). OKF6 cells were treated with CHX, starting 1 hour before infection and 
maintained for the first 2 hours post infection. At 2 hpi, CHX was: maintained (lane 3) 
removed and replaced with DMSO (lane 4); removed and replaced with Actinomycin D 
(lane 5). Total protein lysates were collected at 4 hpi and probed for ICP0, ICP4, Kap1, 
and pKap1-S824. Phosphorylation of Kap1 served as a readout for ATM activity. 
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Chapter 6: Discussion and Future Directions 
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Introduction 
The overall goal of this project was to investigate the interaction between HSV-1 
and the cellular DNA damage response with two aims in mind. The first aim was to 
identify and test potential therapeutic targets for the treatment of oral mucosal HSV-1 
diseases. Our second aim was to identify the mechanisms by which the DDR is activated 
and utilized by HSV-1. We have made great strides in accomplishing both aims. Results 
presented in Chapter 3 demonstrate that oral mucosal HSV-1 infection can be 
suppressed by small molecule inhibitors targeting ATM or Chk2. Chapter 4 includes data 
demonstrating for the first time that ATM signaling has a required function in 
circularization of the HSV-1 genome. Results presented in Chapter 5 reveal that HSV-1 
activates ATM at low levels independently of de novo synthesis, and further activates 
ATM through de novo synthesis of early gene(s) in an ICP4-dependent manner. Herein, 
we will discuss our interpretation of the results, their implications, and directions for 
future research endeavors. 
  
Discussion 
Advancing the Therapeutic Potential for DDR Inhibitors 
  Targeting the DDR has attracted a lot of attention over the past 20 years in 
cancer treatment as an approach to sensitizing cancer to chemotherapeutics. The 
premise of this approach is that combining a DNA damage inducing chemotherapeutic 
with a drug that prevents repair would lead to an increase in cancer cell death or 
targeting a cancer that is deficient in one form of repair with a drug that targets an 
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alternative repair pathway could cause synthetic lethality (e.g. BRCA1 negative cells with 
PARP inhibitors) (404). The DDR is mobilized through signaling cascades mediated by the 
apical kinases ATM, ATR, and DNA-PKcs, and their substrates Chk2 and Chk1. Inhibiting 
one of these factors inactivates the entire signaling network, eliciting a greater effect 
than targeting individual substrates. The first ATM specific compound developed was 
KU-55933 with an IC50 of 12.9 nM (379). A major substrate of ATM is Chk2, which is 
another prime candidate for pharmacological inhibition due to its numerous functions in 
regulating cellular homeostasis. One of the early compounds that demonstrated 
specificity to Chk2 was Chk2 Inhibitor II (BML-277), which inhibits Chk2 with an IC50 of 15 
nM. Treating HSV-1 infected oral mucosal cells with either KU-55933 or Chk2 Inhibitor 
had a profound inhibitory impact on HSV-1 replication (Figure 3.5, 3.7, 3.8). Not only did 
this underscore the necessity of ATM and Chk2 signaling for HSV-1 replication, it 
validated a novel treatment strategy for oral mucosal HSV-1 infection.  
Small molecule inhibitors against ATM or Chk2 have not progressed to clinical 
trials for a variety of reasons. KU-55933 is a lipophilic compound that has very poor 
bioavailability in mice when administered intraperitoneally or intravenously (379). This 
prohibits systemic administration, and has prevented further development of this 
compound.  Meanwhile, the most appropriate therapeutic context for Chk2 inhibition 
has come into question, and this has delayed Chk2 inhibitors from being tested in 
clinical trials (405). While the application of KU-55933 and Chk2 Inhibitor II for cancer 
treatment has been severely hindered by these drawbacks, oral mucosal HSV-1 infection 
presents a different setting where these inhibitors can be utilized. As a cutaneous 
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disease, HSL is commonly treated with the direct application of topical agents, which 
overcomes poor bioavailability properties. Furthermore, both ATM and Chk2 are 
necessary for HSV-1 replication, making them promising candidates for therapeutic 
intervention. When KU-55933 and Chk2 Inhibitor II were reformulated for topical 
delivery, they effectively reduced HSL disease severity in mice (Figure 3.13). This proof-
of-principle result demonstrates that KU-55933 and Chk2 Inhibitor II can be directly 
delivered into the lip mucosal epithelium through topical application and are efficacious 
at treating HSV-1 disease in vivo. Based off of these results, further development of KU-
55933 and Chk2 Inhibitor II compounds for human oral HSV-1 disease is warranted as 
topical delivery can overcome their unfavorable properties.  
 Two of our findings with ATM and Chk2 inhibitors have major implications for 
the management of HSV-1 disease in immunocompromised patients: First, KU-55933 
and Chk2 Inhibitor II can be combined with acyclovir to suppress HSV-1 replication in an 
additive manner (Figure 3.9). Second, KU-55933 and Chk2 Inhibitor II suppress acyclovir-
resistant HSV-1 replication (Figure 3.10). Drug-resistant HSV-1 disease arises in 
immunocompromised patients due to frequent treatments with high concentrations of 
acyclovir. A treatment regimen using a lower concentration of acyclovir could be 
achieved if it were combined with an ATM or Chk2 inhibitor. This would reduce the 
selective pressure exerted by acyclovir, and reduce the chance of a drug-resistant HSV 
strain from emerging. In situations where drug resistance occurs, patients require 
treatment with the highly toxic compounds, foscarnet or cidofovir. Since both foscarnet 
and cidofovir target the HSV-1 DNA polymerase, it can be reasonably assumed that 
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combining either of them with KU-55933 or Chk2 Inhibitor II would also inhibit HSV-1 in 
an additive or synergistic manner. This would enable lower concentrations of foscarnet 
or cidofovir to be used, and significantly reduce side effects associated with these drugs. 
 
The Role of ATM Signaling in HSV-1 Genome Circularization 
 Treatment of HSV-1 infected OKF6 cells with KU-55933 caused a significant 
persistence of HSV-1 genomes in a linear state, demonstrating that ATM signaling has a 
necessary role in circularization (Figure 4.9, 4.10). The manner in which ATM signaling 
facilitates circularization is very interesting, and remains to be determined. While ATM 
signaling is frequently associated with HR, it also facilitates NHEJ under certain 
situations. Since there is evidence of both HR and NHEJ having a role in HSV-1 infection, 
we cannot extrapolate from our result whether circularization occurs through HR or 
NHEJ. 
 The major evidence supporting HR involvement during HSV-1 infection is the 
high levels of recombination that the HSV-1 genome undergoes. Four different 
orientations of the unique long and unique short regions arise in equimolar 
concentration, suggesting that HR occurs at the repetitive a regions. However, 
recombination of the viral genome occurs with the onset of DNA replication, whereas 
circularization occurs prior to genome replication. Thus, HR may have a functional role 
during DNA replication, but not necessarily in the initial hours of infection when 
circularization occurs.  
135 
 
There is also evidence suggesting that the viral genome could be using NHEJ. 
Transfection of HSV-1 DNA into cells induces the phosphorylation of RPA32 on serines 4 
and 8 by DNA-PKcs (389). The NHEJ factors XRCC4 and DNA Ligase IV are required for 
HSV-1 DNA circularization and knock down of these factors impairs HSV-1 replication 
(374). This is a perplexing result because the degradation of DNA-PKcs is well 
characterized in HSV-1 infection (217, 406). However, the degradation of DNA-PKcs by 
ICP0 may create a cellular environment that promotes NHEJ through ATM signaling. It 
has been demonstrated that ATM facilitates V(D)J recombination and class switch 
recombination through NHEJ under situations where DNA-PKcs is knocked down or 
mutated (407-410). A similar situation where ATM signaling facilitating NHEJ may occur 
in HSV-1 infection; this could explain the requirement for XRCC4 and DNA Ligase IV 
while rationalizing the degradation of DNA-PKcs.   
Treatment with KU-55933 resulted in 59.66% of viral genomes persisting in a 
linear state, indicating that a portion of viral genomes were capable of circularizing in 
the absence of ATM signaling. This interesting observation suggests that a secondary, or 
alternative, repair mechanism is being utilized when ATM is inhibited. There is 
significant redundancy in the DDR, in particular between ATM and DNA-PKcs, to ensure 
that damaged DNA gets repaired when one repair mechanism is abrogated (411, 412). 
Circularization occurs within the first couple of hours of infection before DNA-PKcs is 
degraded. To our knowledge, no one has investigated whether DNA-PKcs has an active 
role during this initial phase of HSV-1 infection. Therefore, we tested this hypothesis by 
treating HSV-1 infected cells with a DNA-PKcs specific small molecule inhibitor, NU7441. 
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Our preliminary results suggest that inhibition of DNA-PKcs activity diminishes HSV-1 
replication (Figure 6.1). This supports a hypothesis where DNA-PKcs is used to some 
capacity for circularization and could explain the limited amount of circularization 
detected when ATM is inhibited.   
It is important to stress that circularization of the HSV-1 genome by a secondary 
method may be detrimental for HSV-1 replication. In fact, if the terminal a sequence 
were to be disrupted through a secondary repair mechanism, then replication would be 
inhibited. We do not have direct evidence to indicate whether the structure of 
circularized genomes that arise in the presence of KU-55933 are different from those 
produced under wild type conditions. However, over a 20 hour infection time course, 
treatment with KU-55933 prevented HSV-1 replication to the same degree as acyclovir 
at early and late timepoints (Figure 3.8). If circular genomes could be generated in the 
presence of KU-55933 capable of DNA replication, then HSV-1 genome levels should 
have increased over a 20 hour infection.  
 
The Role of Chk2 Signaling in HSV-1 Infection 
 We conclude that Chk2 activity is not required for circularization of the viral 
genome, but does have a significant role in enabling replication of the viral genome. A 
major function of the Chk2 pathway is to stall the cell cycle at either the G1/S or G2/M 
checkpoints in response to DNA damage (325).  Manipulation of the cell cycle is a 
common feature of viral infections because it keeps the cells stationary in S phase 
where the virus can take advantage of a nuclear environment primed for DNA 
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replication (413). HSV-1 infection causes the cell cycle to stall at both G1/S and G2/M 
through different mechanisms (345, 348). The arrest at G2/M occurs through ATM-
dependent activation of Chk2, which then inhibits Cdc25C by phosphorylating it and 
sequestering it to the cytoplasm as occurs in the DDR (349). It is possible the inhibitory 
effects we see with Chk2 inhibitor II on HSV-1 replication are due to an inability to halt 
the cell cycle. The role for Chk2 inducing G2/M arrest was demonstrated in colorectal 
carcinoma cells, and needs to be assessed in a nontransformed cell line, such as OKF6 or 
hTCEpi (349).  We speculate that treatment with Chk2 Inhibitor II prevents cells from 
stalling at either G1/S or G2/M and this negatively impacts replication of the HSV-1 
genome. This offers an explanation for how Chk2 inhibition can significantly repress 
HSV-1 DNA replication while not impacting circularization.  Furthermore, our results 
with Chk2 Inhibitor II indicate that there are multiple functions downstream of ATM 
signaling that are required for HSV-1 DNA replication. 
 
HSV-1 Activation of ATM through De Novo Synthesis 
We have unequivocally demonstrated that HSV-1 infection causes ATM 
activation with and without de novo synthesis of viral factors. The level of pChk2-T68 
detected when viral gene expression is prohibited by either CHX treatment, UV 
inactivation, or both is significantly reduced, which means that expression of one, or 
more, viral factors is required for full ATM activation (Figure 5.1-5.4). We discovered 
that de novo-dependent activation of ATM requires ICP4 and does not require ICP0 
(Figure 5.6, 5.8). We also determined that synthesis of E genes is a requirement for 
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activation of ATM through de novo synthesis (Figure 5.11). It appears that ICP4 induces 
this robust level of ATM activation through its function as a transactivator of E gene 
expression. However, infection with an ICP4 mutant virus lacking a functional DNA 
binding domain (i13) was fully capable of causing ATM activation (Figure 5.10). These 
opposing results are difficult to reconcile as i13 features a two amino acid insertion in its 
DNA binding domain that abolishes its ability to activate E genes. A possible explanation 
is that the propagation of i13 virus may have produced a large amount of defective viral 
particles that contain tegument factors, which has been shown to happen with other 
mutant HSV-1 viruses (414, 415). Since the complementing cell line produces functional 
ICP4, any tegument-containing particle would be capable of delivering ICP4 into the cell 
it infects. If a higher level of ICP4 was introduced into hTCEpi cells from the tegument of 
i13 virus compared to ICP4Δ, then the effect of the i13 mutant would be masked. The 
number of defective viruses produced across ICP4 mutant strains differ needs to be 
measured to assess the validity of this proposal.   
Precedent has been established that an early gene factor can activate ATM. 
Multiple groups have demonstrated that a mutant HSV-1 strain lacking HSV-1 DNA 
polymerase (HP66), does not activate ATM (343, 416). The requirement for one of the 
HSV-1 replisome factors for ATM activation is perplexing because it has been shown that 
ATM activation occurs when viral DNA synthesis is blocked by PAA or acyclovir (338, 
340, 343). The assembly of the replisome, but not DNA synthesis, may be required for 
recruitment of DDR repair factors to RCs. All 3 components of the MRN complex 
(Mre11, Rad50, and Nbs1) get recruited to RCs (336, 340, 343). The MRN has an 
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important function in recognizing the free DNA ends at a DSB and unwinding it. ATM is 
recruited to DNA through direct interaction with both Nbs1 and Rad50 (417). Mre11 
also has exonuclease activity that is important for resection of dsDNA (292). HSV-1 
infection is suppressed in cell lacking a functional Mre11 (338). Additionally, we have 
discovered that an inhibitor of Mre11 exonuclease activity (Mirin) reduces HSV-1 
replication in a dose-dependent manner (Figure 6.2). These results demonstrate that 
Mre11 has an important role in HSV-1 infection. We hypothesize that formation of the 
HSV-1 replisome recruits the MRN complex to the HSV-1 genome and subsequently 
leads to ATM recruitment and activation.   
 
HSV-1 Activation of ATM Independent of De Novo Synthesis 
Under conditions where de novo synthesis is inhibited by CHX or UV-inactivation, 
a low level of pChk2-T68 is detected. This result is very interesting because indicates 
that somewhere between cell entry and delivery of viral DNA into the nucleus, the 
incoming virion induces ATM activation. Previous findings in our lab using comet assays 
demonstrated that HSV-1 activates ATM without causing DNA DSBs or SSBs in either the 
cellular or viral genome (Alekseev, et al., in preparation). Additionally, transfection of a 
circular bacterial artificial chromosome encoded with the complete HSV-1 genome 
successfully activated ATM, indicating that terminal DNA ends are not required 
(Alekseev, et al., in preparation). These results rule out the possibility of DNA damage or 
terminal HSV-1 ends being the source for ATM activation. Therefore, the de novo-
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independent method of ATM activation may occur through a mechanism analogous to 
other ways ATM is activated independently of DNA damage.  
ATM can be activated through direct or indirect interaction with DNA in the 
absence of a DSB. For example, ATM can be activated after being recruited to DNA 
through MDC1 (418). Tethering the C-terminal portion of ATM to DNA in the absence of 
a DSB also activated ATM signaling with subsequent phosphorylation of H2AX and Chk2 
detected (419). If HSV-1 was equipped with a way to recruit ATM to the genome, ATM 
might be activated as a result of directly binding to the viral genome. In order to 
accomplish this without de novo synthesis, a tegument factor would likely be required. 
ICP4 is a strong candidate to facilitate the recruitment of ATM to the viral DNA because 
it multimerizes on the HSV-1 genome. Also, ICP4 is required for circularization, which, as 
we demonstrated herein, is reliant on ATM signaling (398). This hypotheses assumes 
that ICP4 can either directly or indirectly recruit ATM to HSV-1 genome, which needs to 
be tested. Experimentally, this hypothesis is difficult to test with mutant viruses. As 
shown with ICP4Δ virus, activation of ATM still occurred in the presence of CHX 
treatment (Figure 5.8). ICP4 mutant strains are grown on ICP4 complementing cells and 
progeny virions are packaged with functional ICP4 in the tegument. Therefore, wild type 
ICP4 is still delivered as a tegument factor when cells are infected with ICP4 mutant 
strains. This restriction also applies to ICP0Δ virus. A potential role for ICP0 for initial 
activation of ATM cannot be ruled out because functional ICP0 is packaged into the 
tegument of ICP0Δ virus.  
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Alternatively, HSV-1 may be activating ATM without recruiting it the viral 
genome. HSV-1 infections causes pan-nuclear activation of ATM very early during 
infection before DDR factors coalesce into replication compartments. There are multiple 
mechanisms where ATM is activated in a pan-nuclear manner. Global perturbation of 
chromatin structure, which has been noticed by treating cells with chloroquine, 
hypotonic solutions, or HDAC inhibitors, and reactive oxygen species (ROS) can both 
cause a pan-nuclear activation of ATM (292, 420-423). There is evidence that HSV-1 
infection causes chromatin perturbation and ROS induction, so these methods of ATM 
activation may be relevant.    
Histones get mobilized immediately following DNA delivery into the nucleus, 
which may cause global chromatin perturbations to the cellular genome (424-427). The 
free pools of Histones H1, H2B, and H4 all increase as they are either actively removed 
from cellular chromatin or their re-binding to cellular chromatin is inhibited (425, 426).   
Another hypotheses is that ATM is activated as a response to pressure driven delivery of 
HSV-1 DNA into the nucleus. The temperature sensitive mutant HSV-1 virus, tsB7, 
cannot eject the viral genome into the host nucleus under nonpermissive temperatures. 
We found under these conditions that pChk2-T68 could not be detected, indicating that 
ejection and delivery of the viral genome into the nucleus was required for de novo-
independent activation of ATM (Alekseev, et al., in preparation). The viral genome is 
packaged into a highly pressurized capsid with an internal pressure of 18 atm (199). 
Pressure fluctuations have been shown to disrupt chromatin integrity (428-430). One 
study demonstrated that a 0.2 second impulse with 37.33 atm was a large enough insult 
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to cause DNA fragmentation (431). It is thought that such a pressure impulse induces 
compression and decompression forces on DNA that leads to mechanical disruption 
(431). Since we did not detect DNA damage by comet assay in response to HSV-1 
infection, the ejection of HSV-1 DNA at 18 atm is not sufficient to induce DNA 
fragmentation. However this may be a large enough insult to disrupt chromatin 
integrity. All of these individual observations suggest that the cellular chromatin is 
heavily perturbed in response to HSV-1 infection, and it remains to be seen whether the 
DNA damage response could be triggered by these events. 
 HSV-1 infection produces intracellular ROS, which can directly cause activation of 
ATM. Interestingly, ROS production occurs as early as 1 hour post infection (432, 433). 
Production of ROS in response to HSV-1 activates the innate immune response by 
upregulating NF-κB and IRF3 (432). Since ATM can activate NF-KB, an intriguing 
possibility is that ROS is inducing ATM activation (331). In response to ROS, ATM 
phosphorylates substrates in a unique manner; phosphorylation of p53 and Chk2 occurs 
whereas Kap1 phosphorylation does not (434). This observations is consistent with what 
we observe during the first 2 to 4 hours of HSV-1 infection; pChk2-T68 is detected at a 
high level but pATM-S1981, pKap1-S824, are barely detectable until 4 hpi (Figure 3.2). 
Additional groups have also detected pChk2-T68 within the first hour of infection (338, 
339, 341). Therefore it appears possible that ROS may contribute to the de novo-
independent activation of ATM.  
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Future Directions 
Evaluating the Function of Chk2 in HSV-1 Infection 
 Our results demonstrate that Chk2 signaling is required in the first 3-4 hours of 
infection to activate an essential function for HSV-1 DNA replication. Since Chk2 
signaling is not required for circularization, this implies that the repair signaling 
functions downstream of Chk2 are not needed. Chk2 has previously been reported to 
have a role in HSV-1 by stalling the cell cycle at G2/M, and this should be looked at in 
more detail (349). Of note, the study by Li et al. was performed in colon cancer and 
human embryonic kidney cells, and we have noticed different requirements of the DDR 
between cell types (349). They also presented data to suggest that Chk2 activation occurs 
through ICP0. We have demonstrated in the telomerase immortalized epithelial cell line, 
hTCEpi, that ICP0 is not necessary or required for ATM and Chk2 activation; the 
difference in our results vs those of Li et al. may be the result of cell line difference 
(349). Therefore, experiments should be conducted in OKF6 and hTCEpi cells to 
determine: 1) If the cell cycle is stalled during HSV-1 infection; and 2) if inhibition of 
Chk2 prevents the cell from stalling in response to HSV-1 infection. 
 
Determining the Mechanism of Circularization 
 Having discussed mechanisms by which ATM-dependent circularization can 
occur through either HR or NHEJ, an important future direction would be to determine 
precisely how circularization occurs. This is a challenging endeavor due to the difficulty 
of analyzing the terminal ends. Notably, the termini sequence is directly repeated 
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internally in the genome and the ends are extremely GC rich. These characteristics make 
it very difficult to use any technologies that rely on sequence specific recognition (i.e. 
ChIP, CRISPR). The predominant way circularization is analyzed is through restriction 
digests followed by Southern blots. Using this detection method, future experiments 
can assess the factors needed to convert the linear genome into an endless, circular 
conformation. 
 The first task would be reducing the function of specific NHEJ factors (53BP1, 
Ku70, Ku80, Aretemis, XRCC4, DNA Ligase IV) by shRNA, CRISPR, or small molecule 
inhibitors, and determining if they have a necessary role for circularization. This logic 
can then be applied to test the requirement of HR factors (BRCA1, CtIP, Exo1, MDC1, 
Rad51). Based on these results, a clearer picture will emerge about what events are 
occurring at the DNA ends.  
 
Activation of ATM: Identifying the Responsible Early Genes 
 Identifying the necessary early genes for HSV-1 activation would significantly 
impact our understanding on how ATM is activated and utilized. Since it has already 
been reported that mutant HSV-1 virus (HP66) lacking DNA polymerase cannot activate 
ATM, this suggests that expression of factors in the replisome may be necessary (343, 
416). Therefore, the 7 essential HSV-1 factors essential for HSV-1 DNA replication should 
be tested. OKF6 cells can be infected with viruses featuring mutation of these genes, 
and activation of ATM can be assessed by Western Blot and IF.  
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Activation of ATM: ROS 
 The hypothesis that ROS is the source of de novo-independent activation of ATM 
can be readily tested. First, the production of ROS should be verified in OKF6 cells. 
Second, HSV-1 infected cells can be treated with a ROS scavenger (N-Acetyl-L-cysteine; 
ammonium pyrrolidinedithiocarbamate) and protein lysates can be blotted for pChk2-
T68.     
 
Function of DNA-PKcs 
 As discussed in this chapter, DNA-PKcs may have a previously unrecognized role 
in the first 2 hours of HSV-1 infection. Having shown that a specific inhibitor of DNA-
PKcs (NU7441) reduces HSV-1 replication, a role for DNA-PK seems likely. Since a 
repressive function by DNA-PKcs and NHEJ is well established later during HSV-1 
infection, it is very important that a positive function for DNA-PKcs be verified through 
numerous methods. Initial experiments that can test the role of DNA-PKcs include: 
knockdown of DNA-PKcs by shRNA or CRISPR followed by HSV-1 infection; HSV-1 
infection in matched cell lines that have a mutation in the DNA-PKcs gene rendering it 
nonfunctional, identification of substrates activated by DNA-PKcs in response to HSV-1 
infection 
 
Conclusion 
 In summary, targeting the DDR is an effective strategy for suppressing oral 
mucosal HSV-1 infection that has potential to address unmet clinical needs in managing 
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drug-resistant HSV-1 diseases. We have discovered that circularization of the viral 
genome is one of the major functions of ATM signaling in HSV-1 infection. This 
mechanism is independent of Chk2 signaling, which indicates that Chk2 performs an 
unidentified function that is also required for HSV-1 replication. There is a biphasic 
pattern of ATM activation during HSV-1 infection. The initial phase is independent of de 
novo synthesis, and we can only speculate at this point what mechanism is responsible. 
The second phase of activation occurs through de novo synthesis, and we have 
elucidated that ICP4 has an essential role in this mechanism.    
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Figure 6.1: Inhibition of DNA-PKcs Suppresses HSV-1 Replication. (A) OKF6 cells were 
infected with an MOI of 0.1 and treated with vehicle (DMSO) or 10 µM NU7441. Total 
DNA lysates were collected at 20 hpi and HSV-1 genome levels were quantified by qPCR 
Inhibitor II, or 50 µg/ml Acyclovir. (B) OKF6 cells were infected with HSV-1 at an MOI of 
5 in the presence of vehicle (DMSO) or NU7441 (10 µM). Protein lysates were collected 
at the indicated times and blotted for HSV-1 proteins representing DDR factors and the 
different gene classes: ICPO (IE), ICP8 (E), gB (Leaky Late), and gC (True Late). Nucleolin 
was used as a loading control. 
148 
 
 
 
Figure 6.2: Inhibition of Mre11 Reduces HSV-1 Genome Copy Numbers in a Dose-
Dependent Manner. OKF6 cells were infected with HSV-1 at a MOI of 0.1 and treated 
with a range of Mirin concentrations. Total DNA lysates were collected at 20 hpi, and 
HSV-1 genome levels were quantified by qPCR. Data are means ± SEM. 
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Chapter 7: Experimental Procedures 
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Cells Lines 
OKF6-TERT-2 (OKF6): Normal primary human oral keratinocyte cell line obtained from 
Dr. James Rheinwald (Cell Culture Core of the Harvard Skin Disease Research Center, 
Boston, MA) and cultured in keratinocyte-serum free medium (Gibco) supplemented 
with BPE (25 µg/ml), EGF (0.2 ng/ml), CaCl2 (0.3 mM), 100 units/ml penicillin, and 100 
μg/ml streptomycin.  
293T: Human embryonic kidney cells were maintained in DMEM supplemented with 
10% heat-inactivated FBS, Pen-Strep. 
hTCEpi: Human corneal epithelial cells immortalized with hTERT were a kind gift from 
James Jester at the University of California-Irvine. hTCEpi cells were cultured in 
keratinocyte growth medium-2 supplemented with KGM-1 SingleQuot Kit 
Supplementary Growth Factors (Lonza, Catalog# CC-3107)  
CV-1: African green monkey kidney fibroblasts were grown in DMEM supplemented 
with 10% FBS and Pen-Strep.  
E5: An ICP4 complementing Vero cell line used for propagating ICP4 mutant HSV-1 
strains were a kind gift from Neal DeLuca (University of Pittsburgh). E5 cells were grown 
in DMEM supplemented with 10% FBS and Pen-Strep.   
 
All cells were incubated at 37 °C in 5% CO2. 
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Viruses 
KOS and McKrae: Both KOS and McKrae are wild type HSV-1 strains. KOS was used for in 
vitro experiments while McKrae was used for in vivo experiments. Both were a kind gift 
from Stephen Jennings at Drexel University College of Medicine. 
dlspTK: An acyclovir-resistant strain due to a mutation in the thymidine kinase gene. 
This strain was a kind gift from Donald Coen at Harvard Medical School.  
ICP0Δ (7134): The 7134 strain features mutation in both copies of the ICP0 gene. This 
strain was a kind gift from Nigel Fraser at the University of Pennsylvania. 
ICP4Δ (d120), i13, n208: These HSV-1 strains have mutations in the ICP4 gene. The d120 
strain has a deletion in both copies of the ICP4 gene. The i13 strain has a 2 amino acid 
insertion at amino acid 338 of the ICP4 gene. The n208 strain only expresses the first 
774 amino acids of ICP4. All three viral strains were a kind gift from Neal DeLuca at 
University of Pittsburgh.  
 
Inhibitors and Formulations 
The following drugs were prepared in DMSO and used for in vitro experiments: 
KU-55933 (Tocris Bioscience, Cat. No. 3544), Chk2 Inhibitor II (Sigma-Aldrich, C3742), 
Acyclovir (Sigma-Aldrich, A4669), and Phosphonoacetic Acid (PAA; Alfa Aesar, Lancaster 
Biologicals), Cycloheximide (Calbiochem, 239764), Actinomycin D (ThermoFisher, 11805-
017), NU7441 (SelleckChem, No. S2638), Okadaic Acid (Santa Cruz, CAS 78111-17- 8), 
Mirin (Sigma-Aldrich, M9948). 
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For in vivo experiments, KU-55933 and Chk2 Inhibitor II were prepared in a 5% 
DMSO, 47.5% polyethylene glycol 300, and 47.5% water solution by dissolving 10 mg of 
each compound in DMSO at 50 °C before adding polyethylene glycol, and diluting to 
final volume with water. 
 
Propagation and Harvesting of HSV-1  
 15 cm plates of CV-1 cells at full confluency were infected with HSV-1 at an MOI 
of 0.01 in a 2 ml volume of DMEM (0% FBS). Cells were incubated at 37 °C for 1 hour 
with rocking every 15 mins, 18 ml of DMEM (2% FBS) was added to the plates and 
incubated at 33 °C for 2-3 days. Mutant viruses required a longer incubation time (10-14 
days). For ICP0_ virus, CV-1 cells were infected at an MOI of 0.1. For all ICP4 mutant 
strains (d120, i13, n208), E5 cells were infected instead of CV-1 cells. 
 Once cells fully developed CPE, media was collected off of cells. Then the cells 
were scraped off of the plates and collected. Both the media and cells were spun down 
at 2,000 xg for 10 mins at 4 °C. The supernatant was removed, cell pellets were 
resuspended in a smaller volume of ice-cold PBS, and transferred to a 15 ml conical tube 
where they were spun down at 2,000 xg for 10 mins at 4 °C. The supernatant was 
removed and the cell pellet was resuspended in a small volume (between 750µl and 
1ml) of K-SFM (OKF6 medium). Three rounds of freeze-thaw were performed to lyse 
cells: 20 seconds of vortexing, 10 mins in ethanol dry ice bath, 10 mins at 37 °C. 
Suspension was spun down at 2,000 xg for 10 mins at 4 °C. Virus-containing supernatant 
was then aliquoted into 10 µl amounts and stored at -80 °C. 
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Infection Protocol 
4.0 x 104 cell/ml OKF6 cells were plated in 6 well plates (10 cm plates for 
circularization studies), and grown for 6 days with media changes on days 4 and 5 until 
they reached 90% confluence for HSV-1 infection. Cells were inoculated with HSV-1 for 1 
hour at 37 °C with intermittent rocking. Following inoculation, cells were washed twice 
with PBS before returning medium and incubating in 37 °C until collection. For 
experiments with treatments, inhibitors were preincubated on the cells for 1 hour and 
maintained during inoculation and throughout the remainder of the experiment.  
Synchronized infection was performed by inoculating OKF6 with HSV-1 at 4 °C for 
1 hr to synchronize infection before transitioning to 37 °C. For infection using UV-
inactivated virus, the inoculum was treated with 200 mJ/cm2 UV before added to cells.  
 
Western Blot and Antibodies 
Protein lysates were collected in 2x SDS lysis buffer (12.5 mM Tris pH 6.8; 20% 
glycerol; 4% SDS). Western blots were performed following standard protocols. The 
following antibodies were used: ICP0 (Virusys Corporation, H1A027-100), ICP4 (Santa 
Cruz, sc-69809), Kap1 (BD biosciences, 610680), pKap1-S824 (Bethyl, A300-767A), Chk2 
(Cell Signaling, 3440S), pChk2-T68 (Cell Signaling, 2662), pATM-S1981 (Rockland, 200-
301-400), ATM (Rockland, 600-401-398) , Nucleolin (Santa Cruz, sc-8031), DNA-PKcs 
(Kamiya Biomedical Company, MC-365), alpha tubulin (Cell Signaling, 2144), ICP8 
(mouse monoclonal) was a kind gift from David Knipe at Harvard Medical School, gB 
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(mouse monoclonal) and gC (rabbit polyclonal) were kind gifts from Roselyn Eisenberg 
and Gary Cohen at University of Pennsylvania.  
 
Quantitative Real Time PCR                
HSV-1 genome or transcript levels were measured by quantitative PCR (qPCR). 
Total DNA or RNA lysates were collected from infected cells using the DNeasy Blood & 
Tissue Kit (Qiagen) or the RNeasy Mini Kit (Qiagen). RNA was converted to cDNA using 
qScript (Quanta BioSciencs). Real time quantitative PCR was performed using SYBR 
Green Master Mix (Bio-rad). HSV-1 genome levels were measured using primers 
targeting the HSV-1 gene UL30 and GAPDH for reference. Transcript levels were 
measured using primers targeting ICP0, HSV-1 thymidine kinase, glycoprotein C and 
18sRNA for reference. Primer sequences are listed in Table 7.1. 
 
Kap1 Knockdown and Rescue  
Lentivirus were prepared by co-transfecting 293T cells with 6 µg pLKO.1 
(containing NT shRNA or Kap1 shRNA) and 2 µg of each viral packaging component. 24 
hours after transfection, media was changed to K-SFM (OKF6 medium). Lentivirus was 
collected and filtered 48 hours after transfection and stored at -80ᵒC.  
pLXSN retroviral packagable plasmids containing Kap1 cDNA sequences (A kind 
gift from Yael Ziv, Tel Aviv) were transfected into 293 GPG cells to produce retrovirus. 
Three Kap1 constructs were used: wild type (WT), serine 824 mutated to an alanine 
(S824A), serine 824 mutated to an aspartic acid (S824D). All constructs were resistant to 
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Kap1 shRNA and featured an N-terminal HA tag. They are described in greater detail in 
Ziv et al (319). OKF6 were infected with Kap1 retrovirus and stable cell lines were 
selected for.    
2.0 x 105 OKF6 cells were transduced with NT shRNA, Kap1 shRNA lentivirus, or 
GFP shRNA (control), with media changed the following morning. GFP was expressed in 
control cells 48 hours after transfection and cells were selected with 50 µg/ml 
Hygromycin B.  
 
Indirect Immunofluorescence 
Cells were grown on coverslips and infected as previously described. Cells were 
washed with PBS, fixed with 3% paraformaldehyde/2% sucrose for 10 mins, 
permeabilized with 0.5% Triton X-100 for 5 mins, blocked in 10% donkey serum and 
incubated with primary antibody overnight. Indirect immunofluorescence was carried 
out with primary antibodies: ICP8 (rabbit polyclonal) at a 1:400 dilution (a kind gift from 
Bill Ruyechan at University of Buffalo), ICP8 (mouse monoclonal) at a 1:200 dilution, 
pATM-S1981 at a 1:10,000 dilution, pKap1-S824 at a 1:200 dilution, and nuclei were 
counterstained with Hoechst 33258 (Sigma-Aldrich).  
 
Colony Survival 
 
OKF6 cells were treated with vehicle (DMSO) or KU-55933 (10 µM) for 20 hrs. 
The cells were collected by trypsinization, and a total of 50 cells from vehicle conditions 
156 
 
and 75 cells from KU-55933 treatment were plated into 60 mm tissue culture plates. 
Two weeks later, colonies were fixed with 10% buffered formalin and stained with 
crystal violet. The surviving fraction of cell was calculated. 
 
Southern Blot 
5 µg of DNA was isolated from infected cells, digested with BamH1 overnight, 
and run on a 0.8% agarose gel at 50V for ~7 hours. After imaging, the agarose gel was 
incubated in 1X TAE for 20min, incubated in 0.4 M HCl for 10 mins while rocking, rinsed 
in H2O, and incubated in denaturation solution (0.5 M NaOH, 1.5 M NaCl) for 20 mins 
while rocking. DNA was transferred onto Biodyne B membrane (ThermoScientific, 
77016) through an overnight upward capillary alkaline transfer using 0.4 N NaOH. The 
next day, probes were freshly synthesized as described below. The membrane was 
removed from the transfer apparatus, allowed to air dry for 5 mins, and UV crosslinked 
(Spectrolinker XL-1000 UV Crosslinker, optimal crosslink setting). The membrane was 
blocked in prehybridization buffer (10% dextran sulfate, 5x SSPE, 2% SDS, 1x Denhardt’s 
solution, and 50 mg denatured, sheared salmon sperm DNA) for 2 hrs at 65 °C in a roller 
bottle. The prehybridization buffer was removed and replaced with hybridization buffer 
(prehybridzation buffer with 50 µl of denatured biotinylated ICP4 probe) and incubated 
overnight at 65 °C in a roller bottle. The membrane was washed with 2x SSPE for 5 mins 
twice at RT, 2X SSPE with 1% SDS for 15 mins twice at 65 °C, and 0.1x SSPE for 15 mins 
twice at 65 °C. The membrane was then blocked for 2 hrs, incubated with Streptavidn-
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HRP for 30 mins, washed, and developed using the Chemiluminescent Nucleic Acid 
Detection Module (ThermoScientific, 89880).  
 
Biotinylated Probes 
A plasmid containing the ICP4 gene was digested with BamH1 and AleI, and the 
1.6 kb fragment of DNA corresponding to nucleotides 148,583 to 150,226 of the KOS 
genome (NCBI, Accession JQ673480) was gel-extracted. A Klenow reaction was 
performed at 37 °C for 90 mins using 100 ng of the isolated ICP4 DNA template, 25 ng of 
GC-Rich random hexamer primer (Gene Link, 26-4001-13), 90 µM dATP, 90 µM dTTP, 
210 µM dGTP, 63 µM dCTP, 147 µM Biotin-14-dCTP (Invitrogen, 19518-018), and 10 
units Klenow Fragment 3’-5 exo- (NEB, MO212S). The reaction was terminated with 
EDTA. Ethanol precipitation was performed to remove unincorporated nucleotides. The 
final DNA was resuspended in 50 µl 10mM Tris [pH 8.0].  
 
Mouse Herpes Simplex Labialis Infection and Treatment  
Animal studies were performed in accordance with the Drexel University College 
of Medicine Institutional Animal Use & Care Committee and with the National Institutes 
of Health (NIH) Guide for the Care and Use of Laboratory Animals. 5 week old female 
BALB/c mice were anaesthetized with avertin (250 mg/kg). The lower lip of BALB/c mice 
was abraded by scratching 10 times with a 16 gauge needle while keeping the bevel side 
facing up and infected with 2.0 x 105 PFU HSV-1 (McKrae strain). Mice were treated with 
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inhibitors prepared in a 5% DMSO, 47.5% polyethylene glycol 300, 47.5% water solution. 
Symptoms were scored and weights were measured every 24 hours.    
 
 
Lip Histology 
The lip tissue was dissected from euthanized mice at the completion of the study 
described in Figure 3.13, embedded in O.C.T. Compound (Sakura 4583) and flash frozen 
in liquid nitrogen. Sections were taken and stained with H&E.  
 
Statistical Analysis 
Statistical comparisons were made with unpaired two-tailed Student’s t-test with 
a statistical significance of <0.05. P values are provided in Table S2. 
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 Table 7.1 Oligonucleotide Sequences Used for qPCR 
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Table 7.2 Statistical Analysis 
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